<SEC-DOCUMENT>0001387131-18-002344.txt : 20180524
<SEC-HEADER>0001387131-18-002344.hdr.sgml : 20180524
<ACCEPTANCE-DATETIME>20180524161050
ACCESSION NUMBER:		0001387131-18-002344
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180518
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180524
DATE AS OF CHANGE:		20180524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NANOPHASE TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0000883107
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS PRIMARY METAL PRODUCTS [3390]
		IRS NUMBER:				363687863
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22333
		FILM NUMBER:		18857945

	BUSINESS ADDRESS:	
		STREET 1:		1319 MARQUETTE DRIVE
		CITY:			ROMEOVILLE
		STATE:			IL
		ZIP:			60446
		BUSINESS PHONE:		6303231200

	MAIL ADDRESS:	
		STREET 1:		1319 MARQUETTE DRIVE
		CITY:			ROMEOVILLE
		STATE:			IL
		ZIP:			60446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOPHASE TECHNOLOGIES CORPORATION
		DATE OF NAME CHANGE:	19970305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nanx-8k_052418.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">UNITED STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 8-K</B></FONT><BR>
<FONT STYLE="font-size: 12pt"><B>CURRENT REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 24, 2018 (May 18, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>NANOPHASE
TECHNOLOGIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-22333</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>36-3687863</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jurisdiction of</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1319 Marquette Drive, Romeoville, Illinois
60446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(630) 771-6700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01. Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">On
May 18, 2018, Sol&eacute;sence, LLC (&ldquo;Sol&eacute;sence&rdquo;), a wholly-owned subsidiary of Nanophase Technologies Corporation
(the &ldquo;Company&rdquo;), executed an Amended and Restated Joint Development &amp; Supply Agreement (the &ldquo;2018 Amended
Agreement&rdquo;) with Colorescience Inc. (&ldquo;Colorescience&rdquo;), which agreement is effective as of May 15, 2018. The 2018
Amended Agreement provides for the development and supply of certain sunscreens and skincare products, preparations and formulations
offering protection from one or more environmental effects (defined therein as the &ldquo;Finished Products&rdquo;), innovation
and bridge solution actives and any future products developed under the agreement as mutually agreed by Sol&eacute;sence and Colorescience
(&ldquo;Next Gen Products&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Development of
the Finished Products described in the 2018 Amended Agreement initially began under the Joint Development &amp; Supply Agreement,
dated December 12, 2016, between <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> and Colorescience (the &ldquo;2016
Agreement&rdquo;), a copy of which is filed, with confidential portions redacted, as Exhibit 10.1 hereto.&nbsp; At the time the
2016 Agreement was entered into, the Company determined that the 2016 Agreement was not material to the Company. As product development
progressed, the parties realized that several material changes to the 2016 Agreement were necessary.&nbsp; Those changes led to
the 2018 Amended Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In accordance
with the terms of the 2018 Amended Agreement, <FONT STYLE="background-color: white">Sol&eacute;sence has agreed to produce pilot
and production quantities of the Finished Products and the innovation and bridge solution actives, and the parties have agreed
to work together in good faith on the development of additional products. Under the 2018 Amended Agreement, Colorescience has
agreed to purchase from Sol&eacute;sence, and Sol&eacute;sence has agreed to supply to Colorescience, certain minimum order quantities
of the specified products each year for the term of the agreement. If Colorescience does not meet the minimum order quantities
set forth in the 2018 Amended Agreement and the failure is not due to a force majeure event or a breach or failure of Sol&eacute;sence
to comply with its obligations under the 2018 Amended Agreement, Colorescience may elect to maintain the exclusivity described
below by paying Sol&eacute;sence an additional fee within 60 days after the end of the calendar year or, alternatively, the license
granted to Colorescience described below may be reduced from exclusive to non-exclusive upon written notice thereof by Sol&eacute;sence.
If Colorescience does not intend to meet the minimum order quantities or pay the additional fee in 2019 or a future year, Colorescience
must notify Sol&eacute;sence of such intent by September 30<SUP>th</SUP> of the applicable year. If timely notice is not provided,
Colorescience will be obligated to either meet the minimum order quantity or pay the additional fee for that calendar year. Colorescience
is required to submit purchase orders equal to the annual minimum order quantity for innovation solution actives and Finished
Products or pay the additional fee in the first 60 days after completion of the calendar year. Colorescience is also required
to provide orders to Sol&eacute;sence a minimum of 12 weeks in advance of the requested delivery date</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">In connection with the supply
arrangements described above, Sol&eacute;sence has granted to Colorescience an exclusive license (with certain exceptions noted
in Exhibit F to the 2018 Amended Agreement) to sell, offer to sell, import, market, promote, distribute and use the innovation
solution actives, the Finished Products and any Next Gen Products (collectively, the &ldquo;Exclusive Products&rdquo;) worldwide
in the applicable Exclusive Field, which is defined as (i) with respect to the innovation solution actives, the use in the SPF
50 powder innovation formula for inclusion in environmental protection products which utilize pigmented powder products for use
on human skin using a flow-through brush as the applicator (the &ldquo;Exclusive Application&rdquo;) and are marketed and sold
through any and all channels, and (ii) with respect to the Finished Products and any Next Gen Products, marketing and sales directly
or indirectly to end users through medical offices and facilities, and spas and other facilities with which a medical director
is associated, and other sales by or on behalf of medical professionals, including through the Internet or directly from a medical
professional (the &ldquo;Professional Channel&rdquo;). Sol&eacute;sence has also granted to Colorescience a non-exclusive license
to sell, offer to sell, import, market, promote, distribute and use the bridge solution active worldwide in all fields. Sol&eacute;sence
also granted Colorescience a non-exclusive license to use, for the purpose of promoting and selling the products, certain trademarks
specified in the 2018 Amended Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">For as
long as Colorescience meets the minimum purchase and payment requirements set forth above, neither <FONT STYLE="background-color: white">Sol&eacute;sence
</FONT>nor any of its affiliates is permitted to directly or indirectly develop, manufacture, market, distribute or sell, or license
or grant any third party any rights (including any covenants not to sue) to develop, manufacture, market, distribute or sell:
(i) any <FONT STYLE="background-color: white">sunscreens and skincare products, preparations and formulations offering protection
from one or more environmental effects</FONT> that are covered or claimed by, are developed or manufactured using, embody, incorporate,
utilize, rely on or arise or benefit from any of the specified <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> Technology
(as defined in the 2018 Amended Agreement) (including, without limitation, any and all Exclusive Products), and which are intended
for or are otherwise distributed, marketed and/or sold through the Professional Channel (other than on behalf of Colorescience
pursuant to the 2018 Amended Agreement); or (ii) any such products in any channel that (a) utilize the Exclusive Application or
(b) contain certain ingredients, in each case except for the limited exceptions set forth in Exhibit F to the 2018 Amended
Agreement</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Under the terms of the 2018 Amended Agreement, all Colorescience Technology (as defined therein) and all improvements
made by or on behalf of either party to the Colorescience Technology will be owned exclusively by Colorescience. To the extent
that <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> acquires any interest in any improvements to the Colorescience
Technology, <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> has agreed to assign such interest to Colorescience.
Any trademarks or copyrights filed by Colorescience on products related to independently created or joint intellectual property
will be solely owned by Colorescience. All <FONT STYLE="background-color: white">Sol&eacute;sence </FONT>Technology and all improvements
made by or on behalf of either party to the <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> Technology will be owned
exclusively by <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>. To the extent that Colorescience acquires any interest
in any improvements to the <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> Technology, Colorescience has agreed
to assign such interest to <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>. Intellectual property rights associated
with manufacturing processes that are generally applicable to <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>&rsquo;s
industry and do not contain or reference Colorescience Technology will be the exclusive property of <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>,
and <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> is free to use, license, and/or sell such manufacturing processes
for any application outside of the Exclusive Application at <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>&rsquo;s
sole discretion, provided that Colorescience&rsquo;s rights under the 2018 Amended Agreement are not impaired by such use, license,
or sale. All intellectual property rights developed, created, generated, conceived, authored or reduced to practice jointly by
employees or contractors of Colorescience or its affiliates on the one hand, and employees or contractors of <FONT STYLE="background-color: white">Sol&eacute;sence
</FONT>or its affiliates on the other hand (&ldquo;Joint IP&rdquo;), will be jointly owned by Colorescience and <FONT STYLE="background-color: white">Sol&eacute;sence,
and Colorescience will </FONT>have the exclusive right to market, distribute and sell products covered under Joint IP (&ldquo;Joint
Products&rdquo;). During the term of the 2018 Amended Agreement and subject to the terms of the agreement, <FONT STYLE="background-color: white">Sol&eacute;sence
</FONT>will have the exclusive right to manufacture Joint Products for all applications, including for Colorescience for use within
the Exclusive Field, as well as the exclusive, royalty free right to sell products using the Joint IP for any application outside
of the Exclusive Field. If, however, Colorescience&rsquo;s cumulative purchases of a Finished Product exceed 300,000 units, Colorescience
will become the sole owner of all Joint IP and all intellectual property rights and <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>&rsquo;s
interest therein, including to the formula, related to that Finished Product. Each party has also agreed to keep confidential
information and data relating to, among other things, the other party&rsquo;s business, intellectual property and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The 2018
Amended Agreement will remain in force for an initial 12-year term through May 15, 2030 (the &ldquo;Expiration Date&rdquo;),
which term is renewable for up to two additional five-year terms by mutual agreement of the parties. The 2018 Amended
Agreement may also be terminated prior to the Expiration Date by (i) Colorescience with 120 days&rsquo; notice to <FONT STYLE="background-color: white">Sol&eacute;sence
if Colorescience discontinues its Innovation SPF 50 Powder Sunscreen for any reason; (ii) Colorescience if Sol&eacute;sence </FONT>fails
to timely supply products ordered by Colorescience (a) for more than 60 days and such failure was not due to a force majeure
event or a breach or failure of Colorescience to comply with its obligations under the 2018 Amended Agreement, or (b) for
more than 6 months and such failure was due to a force majeure event, or if <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>
otherwise materially breaches any of the provisions of the 2018 Amended Agreement and such breach is not cured within 75 days
after Colorescience gives written notice of such breach to <FONT STYLE="background-color: white">Sol&eacute;sence</FONT>;
(iii) Colorescience immediately with respect to any product that any governmental or regulatory agency determines to be
unsafe or otherwise prohibits Colorescience from marketing or selling; (iv) Colorescience if <FONT STYLE="background-color: white">any
products violate or infringe any third party intellectual property or other proprietary rights or if any of the
Sol&eacute;sence Technology is adjudicated to be void, invalid or unenforceable; or (v) Sol&eacute;sence if Colorescience (a)
fails to meet the payment terms set forth in the 2018 Amended Agreement and such failure is not cured within 60 days, (b)
becomes insolvent or declares bankruptcy, or (c) otherwise materially breaches the 2018 Amended Agreement </FONT>and such
breach is not cured within 75 days after <FONT STYLE="background-color: white">Sol&eacute;sence</FONT> gives written notice
of such breach to <FONT STYLE="background-color: white">Colorescience (Sol&eacute;sence can then terminate within 60 days of
written notice to Colorescience).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The foregoing description
of the 2018 Amended Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the
2018 Amended Agreement, which is filed, with confidential portions redacted, as Exhibit 10.2 hereto and is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following items are filed as exhibits
to this Current Report on Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 94%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 84%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="ex10-1.htm">10.1*</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-1.htm"><FONT STYLE="font-size: 10pt">Joint Development &amp; Supply Agreement, dated December 12, 2016, by and between <FONT STYLE="background-color: white">Sol&eacute;sence, LLC</FONT> and Colorescience Inc.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-2.htm"><FONT STYLE="font-size: 10pt">10.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="ex10-2.htm">Amended and Restated Joint Development &amp; Supply Agreement, executed by <FONT STYLE="background-color: white">Sol&eacute;sence, LLC</FONT> on May 18, 2018, by and between <FONT STYLE="background-color: white">Sol&eacute;sence, LLC</FONT> and Colorescience Inc.</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">Confidential treatment has been requested with respect
to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: May 24, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">NANOPHASE TECHNOLOGIES CORPORATION</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0pt 0">By:</P>


</TD>
    <TD STYLE="padding-left: 0.25in; border-bottom: Black 1pt solid">/s/ Jess Jankowski</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Name: Jess Jankowski</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>


</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;&nbsp;President &amp; Chief Executive
Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>JOINT DEVELOPMENT & SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><A HREF="nanx-8k_052418.htm">NANOPHASE TECHNOLOGIES CORPORATION &ndash; 8-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>JOINT
DEVELOPMENT &amp; Supply Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supply Agreement (&ldquo;Agreement&rdquo;) is made this
12th day of December, 2016 (&ldquo;Effective Date&rdquo;) between <B>COLORESCIENCE Inc.</B>, a company existing and organized under
the laws of Delaware, with is principal place of business at (&ldquo;<B>COLORESCIENCE</B>&rdquo;) with its principal place of business
at 2141 Palomar Airport Road, Suite 200, Carlsbad, CA 92011, and <B>SOL&Eacute;SENCE, LLC</B>, a company existing and organized
under the laws of Delaware, with its principal place of business at 1319 Marquette Drive, Romeoville, Illinois 60446 (&ldquo;SOL&Eacute;SENCE&rdquo;),
(collectively &ldquo;Parties&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B> both COLORESCIENCE and SOL&Eacute;SENCE desire
to enter into an agreement to develop sunscreen actives and related formulations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD>Provide a near term solution to help bridge the supply gap that is being created by the [*], without losing water resistance
or SPF performance as compared to the performance of the current powder sunscreen products.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Establish a platform technology that will serve as the basis for innovations in sunscreen based products. Enable novel &lsquo;one
of a kind&rsquo; positioning for COLORESCIENCE versus competitive products.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Targeted key enhancements for powder sunscreens are the improvement in adherence and hydrophobicity, while boosting antioxidant
efficacy as measured by Antioxidant Power Method and achieving best in class free radical protection as measured by Radical Status
Factor Method. Both methods are performed by Gematria Laboratories.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD>Targeted key enhancement for liquid products are enhancing PFA while boosting antioxidant efficacy as measured by Antioxidant
Power Method and achieving best in class free radical protection as measured by Radical Status Factor Method. Both methods are
performed by Gematria Laboratories.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B> COLORESCIENCE wishes to exclusively purchase
from SOL&Eacute;SENCE and SOL&Eacute;SENCE wishes to produce and sell exclusively to COLORESCIENCE the Innovation Actives, Finished
Products A and Finished Product B (&ldquo;Exclusive Products&rdquo;) listed in <U>Appendix A</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS </B>The Parties agree that this Agreement shall include
the terms and conditions for the development, supply, and purchase of the Exclusive Products. This Agreement shall reflect the
intentions of both Parties, for further cooperation, joint product development and preferred partnership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Now therefore, for adequate consideration, receipt of which
is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Definitions. </B>For the purpose of clarity, the following terms are used in this Agreement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.1.</FONT></TD><TD><B><I>Sunscreen Active(s):</I></B> Titanium Dioxide, also referred to as TiO<SUB>2</SUB> and Zinc Oxide, also referred to as
ZnO,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.2.</FONT></TD><TD><B><I>Bridge Solution: </I></B>The TiO<SUB>2</SUB> Sunscreen Active developed by SOL&Eacute;SENCE to supply as a replacement
for the [*] materials currently used by COLORESCIENCE in their formulas.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.3.</FONT></TD><TD><B><I>Innovation Solution Active(s): </I></B>The TiO<SUB>2</SUB> and ZnO Sunscreen Actives, either individually or collectively,
covered under the SOL&Eacute;SENCE technology represented by Patent # 9,139,737 and developed specifically and exclusively for
use for the SPF 50 Powder Innovation Formula and the Perfector SPF 50 Innovation Formula and the criteria within Development Objective
2.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.4.</FONT></TD><TD><B><I>SPF 50 Powder Innovation Formula: </I></B>The Powder Sunscreen formula developed by COLORESCIENCE and Sol&eacute;sence
as a replacement for the COLORESCIENCE&rsquo;s current SPF 50 Powder, designed to utilize the Innovation Solution Actives and meet
the requirements of Development Objective 3.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.5.</FONT></TD><TD><B><I>Finished Product A: </I></B>The emulsion/gel product developed by COLORESCIENCE and Sol&eacute;sence for launch by COLORESCIENCE
in [*], but COLORESCIENCE agrees to accept first delivery of Product A by [*]. Development Product A will be manufactured and supplied
to COLORESCIENCE by Sol&eacute;sence as a finished article. The Intellectual Property of Finished Product A may be the ownership
of COLORESCIENCE, SOL&Eacute;SENCE or both, depending on the nature of the program.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.6.</FONT></TD><TD><B><I>Finished Product B</I></B>: COLORESCIENCE and SOL&Eacute;SENCE agree to work toward the development and launch of at
least one additional product within [*] of the launch of Product A.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.7.</FONT></TD><TD><B><I>Supply Agreement</I></B>: A contractual agreement providing the terms and conditions for supply of the Bridge Solution,
the Innovation Solution and the Perfector SPF 50 Innovation Formula by Sol&eacute;sence to COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.8.</FONT></TD><TD><B><I>Exclusive Territory</I>:</B> Region where COLORESCIENCE will have exclusive rights to sell product. COLORESCIENCE will
not have any right to sell the product outside of Exclusive Territory. The Exclusive Territory for this agreement is defined as:
Worldwide</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">1.9.</FONT></TD><TD><B><I>Exclusive Application</I></B><I>:</I> The product area designed for the use of the Innovation Solution Active. The Exclusive
Application for this agreement is defined as: Pigmented powder products for use on human skin using a flow thru brush as the applicator.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD><B>Roles and Responsibilities </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">In order to achieve the timely development
of the Bridge Solution, the Innovation Actives, and Finished Products, COLORESCIENCE and SOL&Eacute;SENCE agree to the following
Roles and Responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">2.1.</TD><TD><B>Roles and Responsibilities of COLORESCIENCE</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.1.1.</TD><TD>Provide the materials and composition of all existing formulations to use the Bridge Solution</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.1.2.</TD><TD>Establish final product launch criteria for the Bridge Solution</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.1.3.</TD><TD>Perform SPF and related clinical testing for confirmation of the performance</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.1.4.</TD><TD>Perform stability testing in conjunction with SOL&Eacute;SENCE of formulas using the Bridge Solution.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.1.5.</TD><TD>Enable production of pilot and production quantities of powder materials as required within the development plans in Appendix
A.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">2.2.</TD><TD><FONT STYLE="font-size: 10pt"><B>Roles and Responsibilities of SOL&Eacute;SENCE</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.1.</TD><TD>Meet the time line provided for the development of the Bridge Solution and the Innovation Solution as provided in Appendix
A</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.2.</TD><TD>Perform the stability testing for Bridge Solution and the Innovation Solution Actives to allow for a minimum three-year shelf
life.</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.3.</TD><TD>Perform the stability testing in conjunction with COLORESCIENCE for the COLORESCIENCE&rsquo;s products using the Bridge solution</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.4.</TD><TD>Perform the stability testing in conjunction with COLORESCIENCE for Finished Product A</TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">COLORESCIENCE</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.5.</TD><TD>Perform the stability testing in conjunction with COLORESCIENCE for Finished Product B</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">2.2.6.</TD><TD>Perform efficacy testing related to Antioxidant Power and Radical Protection Factor to establish these claims with products
produced using the Innovation Solution Actives.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">2.3.</FONT></TD><TD><B><I>Finished Products COLORESCIENCE and </I></B>SOL&Eacute;SENCE <B><I>Obligations</I></B>:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Produce pilot and production quantities of the Bridge
Solution, the Innovation Solution Actives, Finished Product A, and Finished Product B as required within the development plans
in Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD><B>Exclusivity</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3.1.</TD><TD>For so long as COLORESCIENCE meets the minimum purchase and payment requirements as outlined in Exhibit A, neither SOL&Eacute;SENCE
nor any of its affiliates shall directly or indirectly sell any Exclusive Products to any other party other than COLORESCIENCE
within the Exclusive Channels of Distribution in the Territory nor shall SOL&Eacute;SENCE nor any of its affiliates directly or
indirectly sell any Exclusive Products to any party other than COLORESCIENCE for the re-sale or distribution within the Exclusive
Application within the Exclusive Territory (the &ldquo;<U>Exclusivity Commitment</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3.2.</TD><TD>COLORESCIENCE acknowledges that SOL&Eacute;SENCE may at any time sell the Exclusive Products to third parties for resale outside
of Exclusive Territory, provided that, while the Exclusivity Commitment remains in effect, SOL&Eacute;SENCE and its affiliates
shall contractually obligate customers purchasing Exclusive Products for resale or distribution outside the Exclusive Territory
to refrain from reselling or distributing such Exclusive Products for the Exclusive Application within the Exclusive Territory
and will use commercially reasonable efforts to enforce such contractual restrictions. Upon termination of the Exclusivity Commitment,
SOL&Eacute;SENCE shall have no further obligation under this paragraph and may thereafter freely sell Exclusive Products to third
parties for resale through the Exclusive Channels of Distribution in the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">3.3.</FONT></TD><TD>Exclusivity &amp; Development Fee: In exchange for the grant of exclusive rights as contemplated in this agreement, and
                                                                                                 to encourage SOL&Eacute;SENCE to perform under the terms of this agreement and help defray the cost SOL&Eacute;SENCE will
                                                                                                 incur with meeting its responsibilities under this agreement, Client shall pay to SOL&Eacute;SENCE a development fee in the
                                                                                                 amount of $[*], half of which will be due within 30 days of the close of Q1 and half of which will be due at within 30 days
                                                                                                 of the close of Q2. In addition, Client will agree to pay SOL&Eacute;SENCE an additional $[*] in development fees in the
                                                                                                 first quarter of 2018 to support further analytical and development needs in order to support the launch of the Innovation
                                                                                                 SPF50 Powder Sunscreen.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">3.4.</FONT></TD><TD>Success Fee: Client agrees to pay SOL&Eacute;SENCE a Success Fee of $[*] within 30 days of the commercial shipment of the Innovation
SPF50 Powder Sunscreen &ndash; anticipated to occur in Q1 or Q2 of 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3.5.</TD><TD>Minimum Purchase Requirement of Finished Goods</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">3.5.1.</TD><TD>COLORESCIENCE agrees to collectively order the minimum sales quantities appearing on Exhibit A for the Term of the Agreement.
In order for COLORESCIENCE to be bound by the launch requirements and minimum order requirements associated with Finished Products
SOL&Eacute;SENCE must develop such products according to the product profile developed by COLORESCIENCE and with aesthetics and
performance characteristics on par with other production sites contemporaneously being used by Company. The standard for assessing
such quality standards will be solely determined by COLORESCIENCE using a commercially reasonable standard.
In the event that COLORESCIENCE and SOL&Eacute;SENCE do not reach agreement on the aesthetics or performance oft he Finished Products
developed by SOL&Eacute;SENCE, the companies will employ a conumer panel to make final determination of the product attributes
in comparison to the commercially reasonable standard.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">COLORESCIENCE</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">3.5.2.</TD><TD>In the event that COLORESCIENCE does NOT meet the minimum purchase requirement as noted on Exhibit A, the company may pay Solecence
a R&amp;D fee in the amount of [*]% of the difference of such units actually ordered at the Price per Ounce in Exhibit A minus
the minimum units of such products at Price per Ounce. Such difference will be paid within sixty days at the end of each year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">3.5.3.</TD><TD>Such minimum product purchases obligations may be further reduced by the dollars actually purchased by Client of the Innovation
Actives in excess of [*]% above the minimum purchase quantities of such actives. Such &ldquo;Additional Purchases&rdquo; will be
deemed to be a direct offset requirement to the minimum unit of Finished Goods Purchase Obligations above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>4.</B></TD><TD><B>Term and Termination</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">4.1.</FONT></TD><TD><FONT STYLE="font-size: 10pt">This Agreement shall enter into force on the Effective Date and shall remain in force for a ten
(10) year, </FONT>non-cancelable term, renewable for subsequent three year terms upon mutual agreement of both parties <FONT STYLE="font-size: 10pt">(&ldquo;Term&rdquo;)</FONT>.
Notice of termination of the agreement shall be provided not less than 120 days prior to end of any period.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">4.2.</FONT></TD><TD>In the event that COLORESCIENCE discontinues the Innovation SPF50 Powder Sunscreen for whatever reason, COLORESCIENCE will
have the option of terminating this contract within 120 days notice. All fees earned to date shall be owed to <FONT STYLE="font-size: 10pt">SOL&Eacute;SENCE</FONT>.
In the event of such termination, COLORESCIENCE agrees to pay for the actual out of pocket development fees for Finished Products
in development, not to exceed $[*].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>5.</B></TD><TD><B>Commitment to Supply</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">5.1.</FONT></TD><TD>Within 90 days of the Bridge Solution meeting the product profile, development needs and aesthetics of products that such ingredients
were intended for, COLORESCIENCE shall begin to purchase the Bridge Solution. Substantially all of COLORESCIENCE&rsquo;s requirements
for TiO2 shall be supplied by SOL&Eacute;SENCE, as a replacement for [*]. COLORESCIENCE shall provide SOL&Eacute;SENCE a forecast
of COLORESCIENCE&rsquo;s requirements on a quarterly basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">5.2.</FONT></TD><TD>Within 90 days of the Bridge Solution meeting the product profile, development needs and aesthetics of products that such ingredients
were intended for, COLORESCIENCE shall begin to purchase the Bridge Solution. It is the intention of both parties, that a substantial
portion, if not all, of Client&rsquo;s requirements for TiO2and Zinc Oxide shall be supplied by SOL&Eacute;SENCE, either as a replacement
of the Bridge Solution, as the Innovation Active Solution or through the supply of the Finished Product. COLORESCIENCE shall provide
SOL&Eacute;SENCE a forecast of COLORESCIENCE&rsquo;s requirements on a quarterly basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">COLORESCIENCE</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">5.2.1.</TD><TD>It is understood that the Innovation Active Solution is intended to be a critical component of Client&rsquo;s most important
franchise product. SOL&Eacute;SENCE shallenable supply, establish and maintain an inventory equivalent to at least two months inventory
based upon COLORESCIENCE forecast. SOL&Eacute;SENCE will within 120 days of the commercialization of the Innovation Active, qualify
a third party manufacturer (Qualified Manufacturer) to produce the Innovation Active consistent with the specifications in Exhibit
A. Should SOL&Eacute;SENCE be unable for a period of 60 days be unable to supply the Innovation Active for any reason whatsoever,
SOL&Eacute;SENCE shall compell the Qualified Manufacturer to produce the Innovation Active. Upon resumption of production capability,
SOL&Eacute;SENCE shall resume production and supply of the Innovation Active to COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">5.2.2.</TD><TD>Should SOL&Eacute;SENCE due to insolvency be unable to supply the Innovation Active for a period of greater than 60 days, COLORESCIENCE
shall receive a license to have the Qualified Manufacturer said produce and supply the Innovation Active agreement to COLORESCIENCE.
A royalty in the amount of [*]% of the purchase price of the Innovation Active as provided in Exhibit A shall be made payable to
the then owner of Patent # 9,139,737 for all purchases made by or on behalf of COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">5.3.</TD><TD>COLORESCIENCE and SOL&Eacute;SENCE will engage in at least one yearly pipeline development discussion to review additional
products that may be suitable for SOL&Eacute;SENCE to provide COLORESCIENCE. It is both partied intention to continue to explore
future product innovation opportunities together in the liquid product category.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>6.</B></TD><TD><B>Quality of Product</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-size: 10pt">6.1.</FONT></TD><TD>SOL&Eacute;SENCE shall deliver to COLORESCIENCE the Bridge Solution and Exclusive Products that comply with the specifications
set forth in <U>Exhibit B</U> to this Agreement. <U>Exhibit B</U>, which is a part hereof, may be modified from time to time, consistent
with the development of new is the final and exclusive description of the quality and all properties of the Bridge Solution and
the Exclusive Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>7.</B></TD><TD><B>Quantity of Product</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.1</TD><TD>SOL&Eacute;SENCE shall deliver the quantity of Product specified in each order by COLORESCIENCE and COLORESCIENCE shall accept
and pay such quantity of Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">5.2</TD><TD>COLORESCIENCE shall provide SOL&Eacute;SENCE with rolling forecasts of COLORESCIENCE&rsquo;s expected requirements for the
Product (hereinafter referred to as the &ldquo;Forecasts&rdquo;) as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(a)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0">An estimate of the quantity of Product required during the next three (3) months.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">COLORESCIENCE</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0">COLORESCIENCE shall notify SOL&Eacute;SENCE of any changes to these Forecasts as soon as possible to allow SOL&Eacute;SENCE
to make any necessary changes to production schedules.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>8.</B></TD><TD><B>Order Processing and Deliveries</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.1.</TD><TD>SOL&Eacute;SENCE shall accept all orders placed by COLORESCIENCE within three (3) working days from receipt of such orders.
Acceptance of an order by SOL&Eacute;SENCE constitutes a complete and binding contract governed by the terms and conditions of
this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.2.</TD><TD>SOL&Eacute;SENCE shall deliver the Product to COLORESCIENCE. The terms for delivery are FCA Wallingford, Connecticut. All delivery
conditions apply in accordance with the most recent Incoterms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.3.</TD><TD>Title to and risk of loss of Products covered by an Accepted Order shall transfer to COLORESCIENCE upon Delivery (see note
above).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>9.</B></TD><TD><B>Product Returns and Non-Conforming Products</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.1.</TD><TD>Any Non-conforming Product may be returned to SOL&Eacute;SENCE by COLORESCIENCE as set forth in this Article. An entire lot
of Product may be returned to SOL&Eacute;SENCE by COLORESCIENCE as set forth in this Article if a statistically significant sampling
of that lot contains Non-conforming Product. Any acceptance of Product not conforming to the Specifications shall not be deemed
a waiver of the requirement that SOL&Eacute;SENCE conform to the Specifications as to future Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.2.</TD><TD>SOL&Eacute;SENCE shall maintain a quality assurance program and adhere to the quality inspection and testing procedures described
in <U>Appendix D</U>. SOL&Eacute;SENCE shall subject all Product to such quality inspection testing procedures prior to Delivery.
SOL&Eacute;SENCE shall provide COLORESCIENCE with access to its quality inspection testing results upon request.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.3.</TD><TD>All Products shall be subject to inspection and acceptance by COLORESCIENCE. Payment shall not be deemed a waiver of COLORESCIENCE&rsquo;s
right to inspection or acceptance. No inspection, acceptance or payment shall be binding on COLORESCIENCE as to latent defects.
Without limiting any other rights or remedies it may have, COLORESCIENCE, at COLORESCIENCE&rsquo;s option, may (a) store, at SOL&Eacute;SENCE&rsquo;s
expense and subject to COLORESCIENCE&rsquo;s disposal, Non-conforming Products, (b) return Non-conforming Products to SOL&Eacute;SENCE,
(c) require SOL&Eacute;SENCE to repair or replace any Non-conforming Products, (d) require SOL&Eacute;SENCE to issue a credit or
refund to COLORESCIENCE of an amount equal to the amounts paid for any Non-conforming Products, and/or (e) require SOL&Eacute;SENCE
to reimburse COLORESCIENCE for the costs incurred by COLORESCIENCE in procuring conforming goods from an alternate source to the
extent that such costs exceed SOL&Eacute;SENCE&rsquo;s prices (even if not paid) for the Non-conforming Products. SOL&Eacute;SENCE
acknowledges and agrees that the provisions of this Section shall not relieve SOL&Eacute;SENCE of any liability under the warranties
set forth in this Agreement or which SOL&Eacute;SENCE would otherwise lawfully bear even after COLORESCIENCE&rsquo;s inspection
and acceptance.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.4.</TD><TD>All Non-conforming Product returned to SOL&Eacute;SENCE, and all replacement Product shipped by SOL&Eacute;SENCE, will be at
SOL&Eacute;SENCE&rsquo;s risk and expense. Risk of loss of Non-conforming Product returned to SOL&Eacute;SENCE will transfer to
SOL&Eacute;SENCE upon delivery to SOL&Eacute;SENCE&rsquo;s designated carrier (Meaning: FOB shipping point, for COLORESCIENCE only).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">COLORESCIENCE</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.5.</TD><TD>The Minimum Annual Purchase Commitments per Exhibit A shall be reduced by an amount equal to the amount of Non-conforming product
returned to SOL&Eacute;SENCE multiplied by a factor of 2.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>10.</B></TD><TD><B>Representations and Warranties</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.1.</TD><TD>Each Party represents and warrants to the other that it has taken all necessary actions on its part to authorize the execution,
delivery and performance of its obligations undertaken in this Agreement and that this Agreement has been duly executed and delivered
by and on its behalf and constitutes legal, valid and binding obligations enforceable against it in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.2.</TD><TD>SOL&Eacute;SENCE represents and warrants that all Product is and will (i) conform to their applicable Specifications, (ii)
be new, (iii) be free from defects in design, material and workmanship, (iv) be conveyed with good and marketable title, free and
clear of all liens or encumbrances, and (vi) be free from violation or infringement of any third party intellectual property or
other proprietary rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.3.</TD><TD>All warranties set forth in <U>Section 10.1</U> will survive any inspection, delivery, acceptance or payment by COLORESCIENCE.
The warranties set forth in <U>Sections 12.1(a)(i)</U>, <U>12.1(a)(iii)</U> and <U>12.1(a)(v)</U> are made and effective at Delivery,
are continuing and will remain in effect for the longer of Supplier&rsquo;s normal warranty period or for a period of 180 days
following COLORESCIENCE&rsquo;s acceptance of the Product. The warranties set forth in <U>Sections 12.1(a)(ii)</U> and <U>12.1(a)(iv)</U>
are made and effective at Delivery. The warranty set forth in <U>Section 12.1(a)(vi)</U> is made and effective at Delivery, as
is continuing and will remain in effect in perpetuity.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.4.</TD><TD STYLE="text-align: left">If SOL&Eacute;SENCE breaches the warranty contained in <U>Section 12.1(a)(vi)</U>, then without limiting
any other remedies provided by this Agreement or otherwise available to COLORESCIENCE under Law or in equity, COLORESCIENCE may
immediately terminate this Agreement in whole or in part and may immediately cancel any unfilled Accepted Orders without liability.
If a U.S. District Court or any court worldwide adjudges that Product, or any item or part thereof, infringes any United States
Patent or any patent worldwide, irrespective of whether further right of appeal lies available to SOL&Eacute;SENCE, or if Product
or use is enjoined at any stage of the proceedings, any unfilled Accepted Orders will be canceled <I>ipso facto</I> without liability
for COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>11.</B></TD><TD><B>Indemnification</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">11.1.</TD><TD>SOL&Eacute;SENCE shall defend, indemnify and hold COLORESCIENCE and its officers, directors, employees, subcontractors and
agents harmless against and from all damages and claims for damages, suits, causes of action, proceedings, orders, injuries (including
wrongful death) to persons and damages to property of COLORESCIENCE and others, liabilities, losses, fines penalties, recoveries,
judgments or executions, costs (including environmental investigation, remediation, clean-up, response and/or settlement and other
similar costs) which arise out of, are caused by, or are incident to any breach of this Agreement or negligent or otherwise wrongful
act, omission or conduct of SOL&Eacute;SENCE, its agents, employees or subcontractors, or any failure of a Product to meet the
specifications set forth in Exhibit B, except to the extent caused by:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(i)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">any
such failure of a Product actually known by COLORESCIENCE but nevertheless used by COLORESCIENCE; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(ii)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">any
breach of any representation, warranty or covenant made by COLORESCIENCE under this Agreement; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">COLORESCIENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">any
negligent or wrongful act, or other failure by COLORESCIENCE or any of its subcontractors, agents or employees to comply with any
law, ordinance or regulation in connection with the sale or use of the Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0"></TD><TD NOWRAP STYLE="width: 27pt">11.2</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLORESCIENCE shall defend, indemnify and hold SOL&Eacute;SENCE
and its officers, directors, employees, subcontractors and agents harmless against and from all damages and claims for damages,
suits, causes of action, proceedings, orders, injuries (including wrongful death) to persons and damages to property of SOL&Eacute;SENCE
and others, liabilities, losses, fines, penalties, recoveries, judgments or executions, costs (including environmental investigation,
remediation, clean-up, response and/or settlement and other similar costs) which arise out of, are caused by, or are incident to
any breach of this Agreement or any negligent or otherwise wrongful act, omission or conduct of COLORESCIENCE, its agents, employees
or subcontractors, except to the extent caused by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(i)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in">any
failure of a Product to meet the specifications in Exhibit B;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(ii)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in">any
breach of any representation, warranty or covenant made by SOL&Eacute;SENCE under this Agreement; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 -11pt; text-indent: 0.5in">(iii)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.75in">any negligent or wrongful act, or other failure by SOL&Eacute;SENCE or any of its subcontractors, agents or
employees to comply with any law, ordinance or regulation in connection with SOL&Eacute;SENCE&rsquo;s performance of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>12.</B></TD><TD><B>Damages</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">12.1.</TD><TD>Each Party shall be liable to the other for all direct damages arising out of or relating to its performance or failure to
perform under this Agreement, whether based on an action or claim in contract, equity, negligence, tort or otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">12.2.</TD><TD>Neither COLORESCIENCE nor SOL&Eacute;SENCE shall be liable for, nor will the measure of direct damages include, any indirect,
incidental, special, consequential, punitive or exemplary damages or loss of revenue, income, profits or savings arising out of
or relating to its performance or failure to perform under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>13.</B></TD><TD><B>Confidentiality</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.1.</TD><TD>In the course of this Agreement the Parties have and will provide proprietary and confidential information to each other. The
Parties are both &ldquo;Disclosing Party&rdquo; and &ldquo;Receiving Party&rdquo; as the case may be. The term &ldquo;Confidential
Information&rdquo; as used herein shall mean proprietary information including but not limited to any information, know-how, data,
technology, analytical data, mixtures, recipes, formulas, specifications, manufacturing procedures, customer information, strategies
and business plans as well as product samples that are disclosed or provided to the Receiving Party or obtained by their evaluation
(whether tangible or in electronic form). All &ldquo;Confidential Information shall be marked as Confidential.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.2.</TD><TD>The Receiving Party shall, at a minimum, protect and hold in strict confidence all Confidential Information disclosed by the
Disclosing Party, not disclose the Confidential Information to any third party except for its affiliates and will limit disclosure
of Confidential Information within its own organization to its employees or employees of its affiliates whose duties justify the
need to know such Confidential Information and who are bound by appropriate confidentiality obligations as well.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">COLORESCIENCE</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.3.</TD><TD>The Receiving Party shall not use the Confidential Information for any purpose other than the execution of this agreement,
not file any patent or other intellectual property right with regard to the Confidential Information and not commercially exploit
such Confidential Information without the written consent of the Disclosing Party. The Receiving Party shall limit its assessment
of the samples to the cooperation under this Agreement and shall not independently analyse and reverse engineer the received samples
or determine any characteristic and/or the chemical composition of the received sample.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.4.</TD><TD>The foregoing restrictions on disclosure and use shall not be applicable to any Confidential Information which the Receiving
Party can prove through tangible evidence that</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">a)</TD><TD>are in the public domain at the time of disclosure; </TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">b)</TD><TD>are published or otherwise become part of the public domain through no fault of the Receiving Party;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">c)</TD><TD>were in the possession of the Receiving Party at the time of disclosure by the Disclosing Party as shown by prior written records
or became available from a third party who has the right to legally disclose it;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">d)</TD><TD>were independently developed by the Receiving Party without using or making any reference to the Confidential Information;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt">e)</TD><TD>are required to be disclosed pursuant to a law, regulation, rule or ordinance of any governmental body or court having jurisdiction
over either Party provided that the Receiving Party has given prompt written notice of any such requirement prior to any disclosure.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.5.</TD><TD>Confidential Information shall not be considered within the above exceptions merely because the Confidential Information is
embraced by more general information within the exceptions. Any combination of features of Confidential Information shall not be
considered within the above exceptions unless the combination itself and its principles of operation are within the exceptionsl</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.6.</TD><TD>The Receiving Party shall upon written request of the Disclosing Party promptly return all Confidential Information received
from the Disclosing Party and destroy and delete (and confirm such destruction and deletion in writing) all copies thereof (whether
tangible or in electronic form) containing Confidential Information.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.7.</TD><TD>Neither this Agreement nor the disclosure of Confidential Information shall be deemed to constitute the grant of any right
or license under any confidential information.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>14.</B></TD><TD><B>Intellectual Property</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.1.</TD><TD>All Jointly Developed Intellectual Property shall be owned equally by COLORESCIENCE and SOL&Eacute;SENCE. COLORESCIENCE shall
have the exclusive right for the sale of products using the Jointly Developed Intellectual Property and such products developed
will be added to <U>Exhibit B</U> as Jointly Developed Products. SOL&Eacute;SENCE shall have the exclusive right to manufacture
products using the Jointly Developed Intellectual Property for all applications, including the business within the Scope, as well
as the exclusive, royalty free right to sell products using the Jointly Developed Intellectual Property for any application outside
of the Scope.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">14.1.1.</TD><TD>Should Finished Product A be a product developed jointly by Colorescience and Sol&eacute;sence, and COLORESCIENCE cumulative
purchases of Finished Product A exceed 300,000 units, COLORESCIENCE shall become the owner of the formula related to Finished Product
A.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in">14.1.2.</TD><TD>Should Finished Product B be a product developed jointly by Colorescience and Sol&eacute;sence, and COLORESCIENCE cumulative
purchases of Finished Product B exceed 300,000 units, COLORESCIENCE shall become the owner of the formula related to Finished Product
B.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">COLORESCIENCE</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.2.</TD><TD>Process Technology associated with manufacturing processes and compositions associated with the Bridge Solution and Exclusive
Products shall be the exclusive property of SOL&Eacute;SENCE. For the removal of doubt, SOL&Eacute;SENCE shall be free to use,
license, and or sell the Process Technology for any application outside of the Scope at SOL&Eacute;SENCE&rsquo;s sole discretion.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.3.</TD><TD>All Intellectual Property owned by Colorescience developed prior to the establishment of this Joint Development Agreement and
any improvements made to product formulations independently by Colorescience, not related to the Joint Development activities shall
be owned by Colorescience. Any trademarks or copyrights filed by Colorescience on products related to independently created or
Jointly Developed Intellectual Property shall be the sole ownership of Colorescience. Any improvements or inventions resulting
from the development of the SPF50 Innovation Powder Formula, that are not encompassed in the Innovation Solution Actives, will
become the property of COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.4.</TD><TD>All Intellectual Property, including patents, trade secrets, trademarks, or copyrights owned by SOL&Eacute;SENCE developed
prior to the establishment of this Joint Development Agreement Intellectual Property shall remain the sole property of SOL&Eacute;SENCE.
All Intellectual Property related to the Bridge Solution and the Innovation Solution Actives remain the sole property of SOL&Eacute;SENCE,
including any improvements or inventions resulting from the development of the Bridge Solution and the Innovation Solution Actives.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.5.</TD><TD>COLORESCIENCE agrees to use the SOL&Eacute;SENCE tradename, logo and/or trademark on products and/or marketing material utilizing
the Innovation Solution Actives within reason and as practicable by COLORESCIENCE. SOL&Eacute;SENCE, for the purposes of promoting
and selling products containing the Innovation Solution Actives, grants COLORESCIENCE a non-exclusive license to the use of the
SOL&Eacute;SENCE trade name and/or trademark.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>15.</B></TD><TD><B>Notices</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">15.1.</TD><TD>All notices in relation to a breach of this agreement or any demand notes to the other Party shall be in writing and shall
be send to the following contact persons:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">For COLORESCIENCE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Ted Ebel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Function:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Business Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">2141 Palomar Airport Drive</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Carlsbad, CA 92011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phone:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">760-565-5736</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>FAX:</TD>
    <TD>__________________</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">For SOL&Eacute;SENCE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Frank Cesario</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Function:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">1319 Marquette Drive</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Romeoville, Illinois 60446</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phone:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">630-771-6705</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">FAX:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">630-771-????</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLORESCIENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>16.</B></TD><TD><B>Force Majeure</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">16.1.</TD><TD><FONT STYLE="color: #333333">Deliveries or acceptance of the Product may be delayed or suspended by either of the Parties in
the event of Act of God, war, riot, fire, explosion, accident, flood, sabotage, governmental laws, regulations, order or action,
national defense requirements or any other event beyond the reasonable control of such Party, any of which events prevent the manufacture,
shipment, or acceptance or a shipment of the Product If, because of such event, SOL&Eacute;SENCE is unable to supply part or total
demand for the Product or if COLORESCIENCE, because of any such extent, is unable to accept part or total of quantity contracted
for the affected Party shall be exempted to such extent from its obligations hereunder with respect to the particular delivery
involved upon giving prompt notice of such event to the other Party. The other Party shall be likewise exempted from its corresponding
obligations, but this Agreement shall otherwise remain unaffected.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>17.</B></TD><TD><B>Miscellaneous</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ASSIGNMENT:</FONT> This Agreement
shall be binding upon and inure to the benefit of, the successors and permitted assigns of the parties. An assigning party shall
give prompt notice of assignment to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.1.</TD><TD>NO THIRD PARTY BENEFICIARIES. Nothing in this Agreement will confer any benefit or right upon any third party except for the
Parties&rsquo; successors or permitted assignees.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.2.</TD><TD>RELATIONSHIP OF THE PARTIES. Nothing in this Agreement and no action taken by the Parties under this Agreement will constitute
a partnership, joint venture or agency relationship between the Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.3.</TD><TD>COUNTERPARTS. This Agreement may be executed in any number of counterparts, and by the Parties on separate counterparts, but
will not be effective until each Party has executed at least one counterpart. Each counterpart will constitute an original of this
Agreement, but all the counterparts together will constitute but one and the same agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.4.</TD><TD>COSTS AND EXPENSES. Each Party will pay its own costs relating to the negotiation, preparation, execution and performance of
this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.5.</TD><TD>ENTIRE AGREEMENT. This Agreement, together with all Attachments and any other documents incorporated herein constitute the
entire agreement of the Parties with respect to the subject matter in this Agreement, and supersede all prior and contemporaneous
understandings, agreements, representations and warranties, both written and oral, with respect to the subject matter. Each Party
acknowledges that, in entering into this Agreement, it has not relied on any statement, representation, warranty or agreement of
the other Party other than as expressly contained in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.6.</TD><TD STYLE="text-align: left">AMENDMENTS. Any amendment of or variation to this Agreement must be in writing and signed by authorized
representative(s) of both Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.7.</TD><TD>WAIVER. No failure or delay by either Party in exercising any right or remedy provided under this Agreement or by law will
constitute a waiver of that or any other right or remedy, nor will any single or partial exercise of any right or remedy preclude
any other or further exercise of it or the exercise of any other right or remedy. No waiver under this Agreement is effective unless
it is in writing and signed by authorized representative(s) of both Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.8.</TD><TD>SEVERABILITY. If any provision in this Agreement, for any reason, is invalid, illegal or unenforceable, in whole or in part,
in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision of this Agreement or invalidate
or render unenforceable such provision in any other jurisdiction. Upon a determination that any provision is invalid, illegal or
unenforceable, the Parties will negotiate in good faith to modify this Agreement to effect the original intent of the Parties as
closely as possible in a mutually acceptable manner in order that the transactions contemplated herein are consummated as originally
contemplated to the greatest extent possible.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">COLORESCIENCE</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.9.</TD><TD STYLE="text-align: left">NOTICES. All notices provided in connection with this Agreement must be in writing and will be deemed
to have been given (a) when delivered by hand; (b) when delivered if sent by an internationally recognized commercial courier;
(c) on the third (3<SUP>rd</SUP>) day after the first post-mark of the sender&rsquo;s postal service if sent by first class mail,
postage prepaid (return receipt requested, if available). The notices must be sent to the respective Parties at the address of
the contact person set forth in the &ldquo;Description of the Parties&rdquo; (or at such other address for a Party as may be specified
in a notice given in accordance with this Section).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">17.10.</TD><TD>GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the Laws of the United States and the State
of Illinois, as applied to agreements entered into and to be performed entirely within Illinois between Illinois residents, without
giving effect to the principles thereof relating to the conflicts of Laws. The Parties consent to the exclusive jurisdiction and
venue of the State and Federal courts having within their jurisdiction Chicago, Illinois, and hereby agree to irrevocably waive
all objections to personal jurisdiction, venue and <I>forum non conveniens</I>. The Parties exclude application of the United Nations
Convention on Contracts for the International Sale of Goods. COLORESCIENCE AND SOL&Eacute;SENCE HEREBY IRREVOCABLY WAIVE THEIR
RESPECTIVE RIGHTS TO TRIAL BY JURY IN RESPECT OF ANY DISPUTES ARISING UNDER OR RELATED TO THIS AGREEMENT.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>COLORESCIENCE USA, Inc.</B></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><B>SOL&Eacute;SENCE, LLC</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: left; padding-left: 0.25in; border-bottom: Black 1pt solid">/s/ Ted Ebel</TD>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: left; padding-left: 0.25in; border-bottom: Black 1pt solid">/s/ Jess Jankowski</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name: Ted Ebel</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name: Jess Jankowski</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Title: &nbsp;&nbsp;Chief Business Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title: &nbsp;&nbsp;President &amp; Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-left: 0.25in; border-bottom: Black 1pt solid">/s/ Ted Ebel</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.25in; border-bottom: Black 1pt solid">/s/ Kevin Cureton</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name: Ted Ebel</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name: Kevin Cureton</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Title: &nbsp;&nbsp;Chief Business Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title: &nbsp;&nbsp;Vice President of Sales, </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.375in">&nbsp;Marketing &amp; Business Development</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">COLORESCIENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Minimum Annual Purchase Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Bridge Solution &ndash; TiO2</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Innovation Active Solution &ndash; TiO2</FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Innovation Active Solution - ZnO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Price per kg</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$[*]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$[*]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2017 Minimum Annual Purchases (kg)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*] - combined</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2018 Minimum Annual Purchases (kg)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*] - combined</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2019 Minimum Annual Purchases (kg)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*] - combined</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2020 &amp; beyond Minimum Annual Purchases (kg)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">[*]% growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth is sufficient </TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">[*]% growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth is sufficient</FONT></TD>
</TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Finished Products</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Product A &amp; B</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Price per Ounce</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$[*]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">2018 Minimum Annual Purchases (units)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">[*]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">2019 Minimum Annual Purchases (units)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">[*]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">2020 Minimum Annual Purchases (units)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">[*]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">2021&amp; beyond Minimum Annual Purchases (units)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">[*]% growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum is sufficient</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Price per ounce forthe Finished Products is the anticipated price per ounce for a &ldquo;Full Face Product&rdquo; anticipated
to be developed by SOL&Eacute;SENCE assuming a per ounce size of [*] to [*] ounces. In the event that SOL&Eacute;SENCE develops
a &ldquo;Body Product&rdquo;, such price per ounce will be lower. Both parties will work to identify the appropriate unit price
regardless of format to enable Client to support a gross margin on such product of [*]% to [*]%, not including packaging cost.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLORESCIENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Product Specifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COLORESCIENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<DESCRIPTION>AMENDED AND RESTATED JOINT DEVELOPMENT & SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0; text-align: left"><A HREF="nanx-8k_052418.htm">NANOPHASE TECHNOLOGIES CORPORATION &ndash; 8-K</A></P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 10.2</B></P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JOINT DEVELOPMENT &amp; SUPPLY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amended and Restated
Joint Development &amp; Supply Agreement (&ldquo;<B><I>Agreement</I></B>&rdquo;) is made this 15<SUP>th</SUP> day of
May,&nbsp;2018 (&ldquo;Effective Date&rdquo;) between <B>COLORESCIENCE Inc.</B>, a company existing and organized under the
laws of Delaware, (&ldquo;<B><I>COLORESCIENCE</I></B>&rdquo;) with its principal place of business at 2141 Palomar Airport
Road, Suite 200, Carlsbad, CA 92011, and <B>SOL&Eacute;SENCE, LLC</B>, a company existing and organized under the laws of
Delaware, with its principal place of business at 1319 Marquette Drive, Romeoville, Illinois
60446 (&ldquo;<B><I>SOL&Eacute;SENCE</I></B>&rdquo;), (collectively, the &ldquo;<B><I>Parties</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, both COLORESCIENCE and
SOL&Eacute;SENCE desire to develop sunscreen actives and related formulations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Provide a near term solution to help bridge the supply gap that is being created by the [*], without
losing water resistance or SPF performance as compared to the performance of the current powder sunscreen products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Establish a platform technology that will serve as the basis for innovations in sunscreen based
products. Enable novel &lsquo;one of a kind&rsquo; positioning for COLORESCIENCE versus competitive products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Targeted key enhancements for powder sunscreens are the improvement in adherence and hydrophobicity,
while boosting antioxidant efficacy as measured by Antioxidant Power Method and achieving best in class free radical protection
as measured by Radical Status Factor Method. Both methods are performed by Gematria Laboratories.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Targeted key enhancement for emulsions and liquid products are enhancing physical sunscreen performance
while boosting antioxidant efficacy as measured by Antioxidant Power Method, achieving best in class free radical protection as
measured by Radical Status Factor Method and protecting from pollution and other environmental and light sources. Both Antioxidant
Power Method and Radical Status Factor Method are performed by Gematria Laboratories.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS,</B> COLORESCIENCE wishes to
exclusively purchase from SOL&Eacute;SENCE and SOL&Eacute;SENCE wishes to produce and sell exclusively to COLORESCIENCE the Innovation
Solution Actives, Finished Product A, Finished Product B and Next Gen Product(s) (as each is defined herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS,</B> the Parties entered into
that certain Joint Development &amp; Supply Agreement dated December 12, 2016 (the &ldquo;<B><I>Original Agreement</I></B>&rdquo;)
to provide for the development and supply of the Exclusive Products (as defined herein) and related matters as provided therein;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt"><B>WHEREAS,</B> the
Parties desire to amend and restate the Original Agreement in its entirety as set forth below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE</B>, for adequate consideration,
receipt of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify">Definitions. <FONT STYLE="font-weight: normal">For the purpose of clarity, the following terms
are used in this Agreement:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Affiliate(s)&rdquo;</I></B> means any Person (defined below) which directly or indirectly
controls, is controlled by, or under common control with a Party. For purposes of the foregoing definition, the term &ldquo;control&rdquo;
(including with correlative meaning, the terms &ldquo;<B><I>controlling</I></B>&rdquo;, &ldquo;<B><I>controlled by</I></B>&rdquo;,
and &ldquo;<B><I>under common control with</I></B>&rdquo;) as used with respect to any Person, shall mean the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership
of voting securities, by contract, or otherwise. &ldquo;<B><I>Person</I></B>&rdquo; means an individual, corporation, partnership,
limited liability company, firm, association, joint venture, estate, trust, governmental or administrative body or agency, or any
other entity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Bridge Solution&rdquo;</I></B> means the TiO<SUB>2</SUB> Sunscreen Active developed
by SOL&Eacute;SENCE to supply as a replacement for the [*] materials currently used by COLORESCIENCE in their formulas.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;COLORESCIENCE Technology&rdquo;</I></B> means all COLORESCIENCE and COLORESCIENCE
Affiliate Confidential Information, intellectual property and developments (including all trade secrets, know-how, inventions,
designs, concepts, formulations, works of authorship, technical information, manuals, instructions or specifications) owned or
developed by COLORESCIENCE or its Affiliates or provided by COLORESCIENCE or its Affiliates to SOL&Eacute;SENCE in connection with
the activities performed under or contemplated by this Agreement and any Improvements by COLORESCIENCE to any of the foregoing,
including, without limitation, patents, patent applications, trade secrets, know-how, inventions, designs, concepts, Improvements,
technical information, works of authorship, copyrightable materials, including manuals and instructions, Product Specifications,
trademarks, trade dress or trade names, and the Intellectual Property Rights related to any of the foregoing. COLORESCIENCE Technology
includes, without limitation, COLORESCIENCE&rsquo;s existing products, formulations and information, and Improvements or inventions
arising from the development of the SPF 50 Innovation Powder Formula that are not Innovation Solution Actives.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Exclusive Field&rdquo;</I></B> means, on an Exclusive Product-by-Exclusive Product
basis:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">With respect to the Innovation Solution Actives: the use in the SPF 50 Powder Innovation Formula
for inclusion in Environmental Protection Products which utilize the Exclusive Application and are marketed and sold through any
and all channels.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">With respect to Finished Product A, Finished Product B and any Next Gen Products: the Professional
Channel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Environmental Protection Product(s)&rdquo;</I></B> means sunscreens and skincare products,
preparations, and formulations offering protection from one or more environmental effects, including, without limitation, ultraviolet,
infrared and high-energy visible light, pollution, smog, particulates, dust, soot, smoke, acid, chemicals, aerosols, and/or other
hazards and contaminants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.6.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Exclusive Application&rdquo;</I></B> means pigmented powder products for use on human
skin using a flow-through brush as the applicator.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.7.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Exclusive Product(s)&rdquo;</I></B> means the Innovation Solution Actives, Finished
Product A, Finished Product B, and the Next Gen Product.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.8.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Finished Product(s)&rdquo;</I></B> means Finished Product A and Finished Product B.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.9.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Finished Product A&rdquo;</I></B> means the emulsion/gel Environmental Protection
Product developed by COLORESCIENCE and SOL&Eacute;SENCE intended for application to a user&rsquo;s face, provisionally named the
Sunforgettable Total Protection Face Shield.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.10.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Finished Product B&rdquo;</I></B> means the Environmental Protection Product intended
for application to a user&rsquo;s body, provisionally named the Sunforgettable Total Protection Body Shield.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.11.</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Finished Products</I></B>&rdquo; means Finished Product A and Finished Product B.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.12.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Improvements&rdquo;</I></B> means all inventions, discoveries, technical developments
and know-how, including trade secrets, whether or not patentable, conceived and/or reduced to practice by a party that are an improvement,
enhancement and/or modification of a Party&rsquo;s intellectual property and/or technology.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.13.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Innovation Solution Active(s)&rdquo;</I></B> means the TiO2 and ZnO Sunscreen Actives,
the formulations for which have been developed specifically for use with the SPF 50 Powder Innovation Formula and and other product
reformulations as mutually agreed by the Parties and added to <B>Exhibit B</B> to this Agreement from time to time and the criteria
within Development Objective 2.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.14.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Innovation SPF 50 Powder Sunscreen&rdquo;</I></B> means the sunscreen product produced
by COLORESCIENCE containing the SPF 50 Innovation Powder Formula.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.15.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Intellectual Property Rights&rdquo;</I></B> means all trade secrets, copyrights, patents
and other patent rights, trademarks, service marks, moral rights, know-how and any and all other intellectual property or proprietary
rights (including, without limitation, applications relating thereto) in any inventions, compounds, formulations, techniques, works,
know-how or discoveries, whether or not patentable or registrable, now known or hereafter recognized in any jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.16.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Know How&rdquo;</I></B> means all confidential and proprietary information and data
controlled by SOL&Eacute;SENCE as of the Effective Date and Improvements thereto developed or reduced to practice during the Term
of this Agreement that relate to the inventions and technology described in the Patent Rights, including any and all tangible and
intangible information and materials, including research and development data, regulatory submissions and correspondence, manufacturing
information and processes, formulations, assays, cell lines, sequences, composition of matter, constructs, discoveries, improvements,
modifications, processes, methods, protocols, formulas, utility, data (including physical, chemical, biological, toxicological,
pharmacological, preclinical, clinical, and veterinary data), results, inventions, know-how and trade secrets, patentable or otherwise,
and all other scientific, marketing, financial and commercial information or data, but excluding any of the foregoing to the extent
described or claimed in any Patent Rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.17.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Next Gen Product(s)&rdquo;</I></B> means any future products developed under this
Agreement as mutually agreed by the Parties and added to <B>Exhibit B</B> to this Agreement from time to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.18.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Non-Exclusive Product(s)&rdquo;</I></B> means the Bridge Solution.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.19.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Patent Rights&rdquo;</I></B> means: (a) the patents and patent applications listed
on <B>Exhibit C</B> to this Agreement and any other patents and/or patent applications controlled by SOL&Eacute;SENCE and or its
Affiliates at any time during the Term which claim or otherwise cover the Innovation Solution Actives or the use, manufacture or
formulation thereof; (b) any patents and patent applications arising from Improvements covered by Section 14.1.3 of this Agreement;
(c) all regular, divisional, continuation, substitution, continuation-in-part, and continued prosecution applications that claim
priority to those patents or patent applications described in subsections (a) and (b); (c) all patents that have issued or in the
future issue from any of the foregoing patent applications in subsections (a) and (b), including utility, model and design patents,
certificates of invention and applications for certificates of invention; (d) any reissues, renewals, extensions (including patent
term extensions and supplemental certificates and the like), adjustments, re-examinations, revalidations, registrations and pediatric
exclusivity periods of any of the foregoing; and (e) any foreign equivalents of any of the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.20.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Product(s)&rdquo;</I></B> means the Exclusive Products, the Non-Exclusive Products,
the SPF 50 Powder Innovation Formula, and any Environmental Protection Products containing the Innovation Solution Active.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.21.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Product Specifications&rdquo;</I></B> means those specifications, requirements, and
acceptance criteria described in <B>Exhibit B</B> to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.22.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Professional Channel&rdquo;</I></B> means marketing and sales directly or indirectly
to end users through medical offices and facilities, and spas and other facilities with which a medical director is associated,
and other sales by or on behalf of medical professionals, including through the internet or directly from a medical professional.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.23.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Solesence Technology&rdquo;</I></B> means (i) the Patent Rights; (ii) the Know-How;
(iii) all SOL&Eacute;SENCE and SOL&Eacute;SENCE Affiliate Confidential Information, intellectual property and developments (including
all trade secrets, know-how, inventions, designs, concepts, formulations, works of authorship, technical information, manuals,
instructions or specifications) owned or developed by SOL&Eacute;SENCE or its Affiliates or provided by SOL&Eacute;SENCE or its
Affiliates to COLORESCIENCE in connection with the activities performed under or contemplated by this Agreement and any Improvements
by SOL&Eacute;SENCE to any of the foregoing, including, without limitation, patents, patent applications, trade secrets, know-how,
inventions, designs, concepts, Improvements, technical information, works of authorship, copyrightable materials, including manuals
and instructions, Product Specifications, trademarks, trade dress or trade names; (iv) SOL&Eacute;SENCE&rsquo;s and its Affiliates&rsquo;
interest in Joint IP; and (iv) all Intellectual Property Rights related to any of the foregoing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.24.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Solesence Trademarks&rdquo;</I></B> means those trademarks and tradenames of SOL&Eacute;SENCE
listed in <B>Exhibit E</B> to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.25.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;SPF 50 Powder Innovation Formula&rdquo;</I></B> means the Powder Sunscreen formula
developed by COLORESCIENCE as a replacement for COLORESCIENCE&rsquo;s current SPF 50 Powder, designed to utilize the Innovation
Solution Actives and meet the requirements of Development Objective 3.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.26.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Sunscreen Active(s)&rdquo;</I></B> means formulations or preparations of titanium
dioxide (TiO<SUB>2</SUB>) and/or zinc oxide (ZnO) for use in Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.27.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Supply Agreement&rdquo;</I></B> means the contractual agreement entered into by the
Parties providing the terms and conditions for supply of the Bridge Solution and the Exclusive Products by SOL&Eacute;SENCE to
COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.28.</TD><TD STYLE="text-align: justify"><B><I>&ldquo;Territory&rdquo;</I></B> means worldwide.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify">Roles and Responsibilities</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to achieve the timely development
of the Bridge Solution, the Innovation Solution Actives, the Finished Products and the Next Gen Product, COLORESCIENCE and SOL&Eacute;SENCE
agree to the following Roles and Responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1.</TD><TD STYLE="text-align: justify"><B>Roles and Responsibilities of COLORESCIENCE</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1.1.</TD><TD STYLE="text-align: justify">Provide the materials and composition of all existing formulations to use the Bridge Solution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1.2.</TD><TD STYLE="text-align: justify">Establish final product launch criteria for the Bridge Solution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1.3.</TD><TD STYLE="text-align: justify">Perform SPF and related clinical testing for confirmation of the performance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1.4.</TD><TD STYLE="text-align: justify">Perform stability testing in conjunction with SOL&Eacute;SENCE of formulas using the Bridge Solution;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1.5.</TD><TD STYLE="text-align: justify">Enable production of pilot and production quantities of powder materials as required within the
development plans in <B>Exhibit A</B> to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2.</TD><TD STYLE="text-align: justify"><B>Roles and Responsibilities of SOL&Eacute;SENCE</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.1.</TD><TD STYLE="text-align: justify">Meet the timeline provided for the development of the Bridge Solution and the Innovation Solution
Actives as provided in Exhibit A;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.2.</TD><TD STYLE="text-align: justify">Perform the stability testing for Bridge Solution and the Innovation Solution Actives to allow
for a minimum three-year shelf life;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.3.</TD><TD STYLE="text-align: justify">Perform the stability testing in conjunction with COLORESCIENCE for the COLORESCIENCE&rsquo;s products
using the Bridge solution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.4.</TD><TD STYLE="text-align: justify">Perform the stability testing in conjunction with COLORESCIENCE for Finished Product A;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.5.</TD><TD STYLE="text-align: justify">Perform the stability testing in conjunction with COLORESCIENCE for Finished Product B; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2.6.</TD><TD STYLE="text-align: justify">Perform efficacy testing related to Antioxidant Power and Radical Protection Factor to establish
these claims with products produced using the Innovation Solution Actives.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3.</TD><TD STYLE="text-align: justify"><B>Production Obligations</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3.1.</TD><TD STYLE="text-align: justify">SOL&Eacute;SENCE shall produce pilot and production quantities of the Bridge Solution, the Innovation
Solution Actives, Finished Product A, and Finished Product B as required within the development plans in Exhibit A.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3.2.</TD><TD STYLE="text-align: justify">Without limiting the generality of the foregoing, SOL&Eacute;SENCE shall develop and deliver to
COLORESCIENCE Finished Product A for launch by COLORESCIENCE by [*] and COLORESCIENCE agrees to accept first delivery of Finished
Product A. SOL&Eacute;SENCE shall develop and deliver to COLORESCIENCE Finished Product B by [*]. Each Finished Product will be
manufactured and supplied to COLORESCIENCE by SOL&Eacute;SENCE as a finished article in accordance with all product specifications
and applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4.</TD><TD STYLE="text-align: justify">Branding; Promotional Materials. COLORESCIENCE will promote and sell the Products under trademarks
selected by COLORESCIENCE, which trademarks shall be owned and shall remain the property of COLORESCIENCE. COLORESCIENCE shall
have the right but not the obligation to use SOL&Eacute;SENCE Trademarks on Products utilizing the Innovation Solution Actives
and/or related marketing materials when reasonable and practicable at the sole discretion of COLORESCIENCE. Except as set forth
in this Section 2.4, nothing herein shall be deemed to give SOL&Eacute;SENCE, its Affiliates, and/or their respective suppliers,
either during the Term or thereafter, any right to trademarks or copyrights of COLORESCIENCE or to their use unless written consent
is obtained from COLORESCIENCE. COLORESCIENCE will create and develop all promotional materials with respect to the Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.5.</TD><TD STYLE="text-align: justify">Patent Marking. COLORESCIENCE agrees, to the extent commercially reasonable and consistent with
prevailing business and legal practices, to mark and use reasonable efforts to have each of its Affiliates and sublicensees mark
all Products covered by the Patent Rights under this Agreement in accordance with the applicable statute or regulations relating
to patent marking in the country or countries of manufacture and sale thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.6.</TD><TD STYLE="text-align: justify">Development. The Parties shall work together in good faith, using commercially reasonable efforts,
on the development of two additional products during the first thirty (30) months of the Term. COLORESCIENCE and SOL&Eacute;SENCE
will engage in at least one yearly pipeline development discussion to review additional products that may be suitable for SOL&Eacute;SENCE
to provide COLORESCIENCE. It is both Parties intention to continue to explore future product innovation opportunities together
in the liquid product category.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify">Exclusivity</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1.</TD><TD STYLE="text-align: justify">SOL&Eacute;SENCE License Grant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1.1.</TD><TD STYLE="text-align: justify">Exclusive License. SOL&Eacute;SENCE hereby grants to COLORESCIENCE an exclusive (even as against
SOL&Eacute;SENCE and its Affiliates except with respect to its development and manufacturing obligations hereunder and the exceptions
noted on <B>Exhibit F</B> to this Agreement) license under the Solesence Technology to sell, offer to sell, import, market, promote,
distribute and use Exclusive Products in the Territory in the applicable Exclusive Field.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1.2.</TD><TD STYLE="text-align: justify">Non-Exclusive License. SOL&Eacute;SENCE hereby grants to COLORESCIENCE a non-exclusive license
under the Solesence Technology to sell, offer to sell, import, market, promote, distribute and use Non-Exclusive Products in the
Territory in all fields.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1.3.</TD><TD STYLE="text-align: justify">Trademarks. SOL&Eacute;SENCE hereby grants to COLORESCIENCE a non-exclusive license to use, for
the purposes of promoting and selling Products containing the Innovation Solution Actives, the Solesence Trademarks. Prior to,
and after, the use of Solesence Trademarks, COLORESCIENCE shall inform SOL&Eacute;SENCE of the planned method of use of the trademark.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2.</TD><TD STYLE="text-align: justify">Sublicensing. COLORESCIENCE shall have the right to grant sublicenses for the licenses and rights
granted under this Agreement and to otherwise utilize one or more Affiliates and/or third parties to distribute, market and/or
promote the Products to the same extent that COLORESCIENCE holds such rights, without the consent of or notice to SOL&Eacute;SENCE.
COLORESCIENCE shall be responsible for ensuring that any of its sublicensees&rsquo; exercise of such rights complies with the terms
of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3.</TD><TD STYLE="text-align: justify">Sufficiency of Licensed Rights. SOL&Eacute;SENCE hereby represents and warrants that neither it
nor its Affiliates owns or controls any Intellectual Property Rights, other than the licenses and rights granted to COLORESCIENCE
under this Agreement, covering, claiming or directed to any Products or the formulation, development, manufacture, use, sale, offer
for sale, import or other commercial exploitation thereof in accordance with the terms of this Agreement by COLORESCIENCE and/or
its Affiliates and/or each of their respective successors, assigns (including successors and/or assigns to any Products or Product
lines of COLORESCIENCE and/or its Affiliates), suppliers, distributors, resellers, customers, agents, licensees (or sublicensees),
or agents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4.</TD><TD STYLE="text-align: justify">For so long as COLORESCIENCE meets the minimum purchase and payment requirements as provided in
Exhibit A and further described in Section 3.7 below and without limiting the exclusive rights granted under Section 3.1, neither
SOL&Eacute;SENCE nor any of its Affiliates shall directly or indirectly develop, manufacture, market, distribute or sell, or license
or grant any third party any rights (including any covenants not to sue) to develop, manufacture, market, distribute or sell: (i)
any Environmental Protection Products that are covered or claimed by, are developed or manufactured using, embody, incorporate,
utilize, rely on or arise or benefit from any of the Solesence Technology (including, without limitation, any and all Exclusive
Products), and which are intended for or are otherwise distributed, marketed and/or sold through the Professional Channel (other
than on behalf of COLORESCIENCE pursuant to this Agreement); or (ii) any Environmental Protection Products in any channel that
(a) utilize the Exclusive Application or (b) contain [*] or [*] (all of the above, collectively, &ldquo;<B><I>Competing Products</I></B>&rdquo;);
except for the limited exceptions set forth in <B>Exhibit F </B>(the obligations of SOL&Eacute;SENCE and its Affiliates under this
Section 3.4, the &ldquo;<B><I>Exclusivity Commitment</I></B><I>&rdquo;</I>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5.</TD><TD STYLE="text-align: justify">Exclusivity &amp; Development Fee: In exchange for the grant of exclusive rights as contemplated
in this Agreement, and to encourage SOL&Eacute;SENCE to perform under the terms of this Agreement and help defray the cost SOL&Eacute;SENCE
will incur with meeting its responsibilities under this agreement, the Parties acknowledge that COLORESCIENCE has paid to SOL&Eacute;SENCE
a development fee in the amount of $[*]. In addition, the Parties acknowledge that COLORESCIENCE has paid to SOL&Eacute;SENCE
an additional $[*] in development fees in the first quarter of 2018 to support further analytical and development needs in order
to support the launch of the Innovation SPF 50 Powder Sunscreen.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6.</TD><TD STYLE="text-align: justify">Success Fee: COLORESCIENCE agrees to pay SOL&Eacute;SENCE $[*] within thirty (30) days after COLORESCIENCES&rsquo;
first commercial sale of the Innovation SPF 50 Powder Sunscreen, which is anticipated to occur in Q1 or Q2 of 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">3.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Minimum Order Quantities of Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7.1.</TD><TD STYLE="text-align: justify">Subject to SOL&Eacute;SENCE&rsquo;s compliance with this Agreement, including timely fulfilling
its supply obligations hereunder, COLORESCIENCE agrees to collectively order the minimum order quantities appearing on Exhibit
A (the &ldquo;<B><I>Minimum Order Quantity(ies)</I></B>&rdquo;) for the Term of this Agreement, provided that, with respect to
Finished Products, SOL&Eacute;SENCE shall have developed such Finished Products according to the applicable Product Specifications
developed by COLORESCIENCE and with aesthetics and performance characteristics on par with other production sites contemporaneously
being used by COLORESCIENCE. The standard for assessing such quality standards will be solely determined by COLORESCIENCE using
a commercially reasonable standard. In the event that COLORESCIENCE and SOL&Eacute;SENCE do not reach agreement on the aesthetics
or performance of the Finished Products developed by SOL&Eacute;SENCE, the Parties will employ a consumer panel to make final determination
of the product attributes in light of commercially reasonable standards.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7.2.</TD><TD STYLE="text-align: justify">In the event that COLORESCIENCE does NOT meet the Minimum Order Quantity for a Product as provided
in Exhibit A and such failure was not due to a Force Majeure Event or a breach or failure of SOL&Eacute;SENCE to comply with its
obligations under this Agreement, COLORESCIENCE may elect, subject to Section 3.7.3 below, to maintain exclusivity by paying SOL&Eacute;SENCE
an R&amp;D fee (the &ldquo;<B><I>R&amp;D Fee</I></B>&rdquo;) within sixty days after the end of each calendar year, as follows:</TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: normal; text-align: justify; font-size: 10pt"><B>Product</B></TD>
    <TD STYLE="width: 66%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: normal; text-align: justify; font-size: 10pt"><B>R&amp;D Fee</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Bridge Solution</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Innovation Solution Active</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: normal; text-align: justify; font-size: 10pt">[*]% of the difference of (i) the value of the units actually ordered at the Price per Ounce in Exhibit A, minus (ii) the value of the Minimum Order Quantity of the Product at the Price per Ounce in Exhibit A</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: normal; text-align: justify; font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 5.4pt">Finished Products A and B, and Next Gen Product(s),&nbsp;&nbsp;collectively</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: normal; text-align: justify; font-size: 10pt; padding-bottom: 5.4pt">The greater of (i) $[*] or (ii) [*]% of the average purchase price of the units of Finished Products purchased, multiplied by the difference between (a) the Minimum Order Quantity of Finished Products and (b) the number of units of Finished Products actually purchased by COLORESCIENCE</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">In the event
COLORESCIENCE does not meet the Minimum Order Quantities provided in Exhibit A with respect to a Product and does not timely pay
the R&amp;D Fee, and if COLORESCIENCE&rsquo;s inability to meet the Minimum Order Quantity did not result from a Force Majeure
Event or SOL&Eacute;SENCE&rsquo;s breach or failure to comply with its obligations under this Agreement, including to timely supply
such Product in accordance with the Product Specifications, then as SOLESENSE&rsquo;s sole and exclusive remedy and COLORESCIENCES&rsquo;s
sole and exclusive liability, the license granted in Section 3.1 and the Exclusivity Commitment provided in Section 3.4 with respect
to such Product may be reduced from exclusive to non-exclusive upon written notice thereof by SOL&Eacute;SENCE. Notwithstanding
the foregoing, in the event that COLORESCIENCE does not intend to meet the Minimum Order Quantities or pay the pro-rated R&amp;D
Fee in 2019 or a future year as a result of such shortfall, COLORESCIENCE shall notify SOL&Eacute;SENCE of such intent by September
30, of that year. If COLORESCIENCE fails to timely provide such notification, COLORESCIENCE shall be obligated to either meet the
Minimum Order Quantity or pay the shortfall R&amp;D Fee for that calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">3.7.3.</TD><TD STYLE="text-align: justify">Should SOL&Eacute;SENCE sell to COLORESCIENCE any units
of Finished Products A, B, or Next Gen Product(s) intended for use in a marketing campaign or as full-sized testers at a sales
price lower than the pricing provided in Exhibit A (such lower price, the &ldquo;<B><I>Reduced Sales Price</I></B>&rdquo;) then
the quantities of such Products sold at the Reduced Sales Price shall contribute towards the applicable Minimum Order Quantities
at a prorated amount equal to the Reduced Sales Price as a percentage of the price provided in Exhibit A multiplied by the total
units sold at the Reduced Sales Price. For clarity any non-full-sized samples (including luxury samples) created for Colorescience
shall not be included towards the applicable Minimum Order Quantity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7.4.</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in this Section 3.7, COLORESCIENCE shall submit purchase
orders equal to the annual minimum order quantity for Innovation Actives and Finished Products as listed in Exhibit A or pay the
equivalent pro-rated R&amp;D Fee, in the first sixty 60 days after the completion of the calendar year of the agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7.5.</TD><TD STYLE="text-align: justify">If in a given year COLORESCIENCE exceeds the previous year&rsquo;s Minimum Order Quantity for a
Product, then the Minimum Order Quantity for such Product shall be reduced by one half of the previous year&rsquo;s excess (Offset),
while under no circumstance shall COLORESCIENCE pay less than [*]% of the Minimum Order Quantity even after accounting for the
Offset.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify">Term and Termination</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1.</TD><TD STYLE="text-align: justify">This Agreement shall enter into force on the Effective Date and shall remain in force for a twelve
(12) year, non-cancelable term, renewable upon written notice for up to two (2) additional five (5) year terms upon mutual agreement
of both parties (altogether, the &ldquo;<B><I>Term</I></B>&rdquo;). Notice of intent to renew this agreement shall be provided
not less than sixty (60) days prior to end of the current Term.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2.</TD><TD STYLE="text-align: justify">Termination by COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.1.</TD><TD STYLE="text-align: justify">In the event that COLORESCIENCE discontinues the Innovation SPF 50 Powder Sunscreen for any reason,
COLORESCIENCE shall have the right to terminate this Agreement upon 120 days&rsquo; notice to SOL&Eacute;SENCE. All fees earned
to date shall be owed to SOL&Eacute;SENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.2.2.</TD><TD STYLE="text-align: justify">If SOL&Eacute;SENCE (a) fails to timely supply, according
to the terms of supply as provided by Section 8, any Products ordered by COLORESCIENCE for a period of greater than sixty (60)
days and such failure was not due to a Force Majeure Event or a breach or failure of COLORESCIENCE to comply with its obligations
under this Agreement, (b) fails to timely supply, according to the terms of supply as provided by Section 8, any Products ordered
by COLORESCIENCE for a period of greater than six (6) months and such failure was due to a Force Majeure Event, or (c) otherwise
materially breaches any of the provisions of this Agreement and such breach is not cured within seventy-five (75) days after COLORESCIENCE
gives written notice of such breach to SOL&Eacute;SENCE, then COLORESCIENCE shall have the right to: (i) use a third-party manufacturer
to supply such Products as provided in Section 5.1.2 until such time that SOL&Eacute;SENCE cures the breach; or (ii) terminate
this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.3.</TD><TD STYLE="text-align: justify">COLORESCIENCE shall have the right to terminate this Agreement immediately with respect to any
Product that any governmental or regulatory agency (including, by way of example, the U.S. Food and Drug Administration) determines
to be unsafe or otherwise prohibits COLORESCIENCE from marketing or selling.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2.4.</TD><TD STYLE="text-align: justify">If SOL&Eacute;SENCE breaches the warranty contained in Section 10.2.6(e), or if any of the Solesence
Technology is adjudicated to be void, invalid, or unenforceable, then without limiting any other remedies provided by this Agreement
or otherwise available to COLORESCIENCE under law or in equity, COLORESCIENCE may immediately terminate this Agreement, in whole
or in part, and may immediately cancel any unfilled accepted orders without liability. If a U.S. District Court or any court worldwide
adjudges that any Product, or any item or part thereof, or the use thereof infringes any United States patent or any patent worldwide,
irrespective of whether further right of appeal lies available to SOL&Eacute;SENCE, or if any Product or use thereof is enjoined
at any stage of the proceedings, any unfilled accepted orders will be canceled without liability for COLORESCIENCE</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3.</TD><TD STYLE="text-align: justify">Termination by SOL&Eacute;SENCE: If COLORESCIENCE: (a) fails to meet payment terms as provided
in Section 8 of this agreement and does not cure within another sixty (60) days; (b) becomes insolvent or declares bankruptcy,
or (c) otherwise materially breaches this Agreement and such breach is not cured within seventy-five (75) days after SOL&Eacute;SENCE
gives written notice of such breach to COLORESCIENCE, then SOL&Eacute;SENCE shall have the right to terminate this agreement upon
60 days of written notice to COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4.</TD><TD STYLE="text-align: justify">Effect of Termination. Subject to the exceptions set forth in this paragraph, in the event of termination
of this Agreement for any reason, the licenses and rights granted hereunder by SOL&Eacute;SENCE to COLORESCIENCE shall terminate,
and shall revert to SOL&Eacute;SENCE, and COLORESCIENCE shall not thereafter make any use whatsoever of the SOL&Eacute;SENCE Trademarks
or the Products. Notwithstanding the foregoing, the licenses and rights granted under this Agreement by SOL&Eacute;SENCE to COLORESCIENCE
shall remain in full force and effect: (i) upon exercise by COLORESCIENCE of its right to use a third-party to supply Product pursuant
to Section 4.2.2, with no further payment obligations to SOL&Eacute;SENCE, and without prejudice to any other remedies COLORESCIENCE
may have against SOL&Eacute;SENCE or that SOL&Eacute;SENCE may have against COLORESCIENCE for such breach; and (ii) upon termination
of this Agreement for any reason, for the shelf life of any Products manufactured or in process prior to the date of termination
of this Agreement in order to provide COLORESCIENCE and its Affiliates, sublicensees, resellers, distributors, marketing partners,
agents and assigns sufficient time to sell off the existing inventory of the Products or related marketing materials (including,
at COLORESCIENCE&rsquo;s option, orders in process and/or in SOL&Eacute;SENCE&rsquo;s possession but not yet completed or shipped),
provided that COLORESCIENCE shall continue to pay any amounts payable thereon as provided in this Agreement. COLORESCIENCE shall
remain obligated to meet any payment obligations to SOL&Eacute;SENCE or its permitted assigns established prior to the termination
of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.5.</TD><TD STYLE="text-align: justify">The rights and obligations of each of the Parties hereto under any provision of this Agreement,
which, by its terms, is intended to survive beyond the term of this Agreement, shall continue notwithstanding the expiration or
termination of this Agreement for any reason.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: justify">Commitment to Supply</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1.</TD><TD STYLE="text-align: justify">COLORESCIENCE shall provide SOL&Eacute;SENCE a forecast of COLORESCIENCE&rsquo;s requirements for
Products on a quarterly basis as provided in Section 7.2 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1.1.</TD><TD STYLE="text-align: justify">It is understood that the Products are intended to be a critical component of COLORESCIENCE&rsquo;s
most important franchise products. SOL&Eacute;SENCE shall enable supply, establish and maintain an inventory at its facility equivalent
to at least three months&rsquo; supply based upon COLORESCIENCE&rsquo;s most recent forecasts, provided that with respect to the
Innovation Solution Actives, SOL&Eacute;SENCE shall maintain an inventory at its facility equivalent to at least six months&rsquo;
supply based upon COLORESCIENCE&rsquo;s most recent forecasts. SOL&Eacute;SENCE will within 120 days of the commercialization of
each Product, qualify a third party manufacturer (the &ldquo;<B><I>Qualified Manufacturer</I></B>&rdquo;) acceptable to COLORESCIENCE
to produce such Product consistent with the Product Specifications. Should SOL&Eacute;SENCE be unable for a period of 60 days to
supply any Products for any reason whatsoever, SOL&Eacute;SENCE shall compel the Qualified Manufacturer to produce such Products
on SOL&Eacute;SENCE&rsquo;s behalf. Upon resumption of production capability, SOL&Eacute;SENCE shall resume production and supply
of such Products to COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.2.</TD><TD STYLE="text-align: justify">Should SOL&Eacute;SENCE due to insolvency, breach,
Force Majeure Event or any other reason be unable or otherwise fail to supply any Products for a period of greater than 75 days
(provided that in the event of a Force Majeure Event, such period shall be greater than six (6) months), and such failure was
not due to a breach or failure of COLORESCIENCE to comply with its obligations under this Agreement, COLORESCIENCE shall have
the right to have the Qualified Manufacturer or, if such Qualified Manufacturer is unable to meet the supply obligations under
this Agreement, an alternative manufacturer chosen by COLORESCIENCE, produce and supply such Products directly for COLORESCIENCE,
until such time as SOL&Eacute;SENCE can resume supply. Any agreement between SOL&Eacute;SENCE and the Qualified Manufacturer shall
provide that COLORESCIENCE shall have the right to purchase Products at prices no greater than the prices provided in this Agreement.
To the extent such price is less than that provided under this Agreement, COLORESCIENCE agrees to provide such differential to
the then owner of U.S. Patent 9,139,737 provided that (i) such Patent Rights has validly issued claim covering such Product at
the time of manufacture and (ii) in no event shall such royalty payment constitute more than [*]% of the total purchase price
of such Product from the Qualified Manufacturer. COLORESCIENCE and the Qualified Manufacturer shall only have the rights to use
SOL&Eacute;SENCE technology for the manufacture of Products. SOL&Eacute;SENCE maintains all rights to take legal action should
Qualified Manufacturer alone or by the direction of COLORESCIENCE or COLORESCIENCE use SOL&Eacute;SENCE technology for other than
the manufacture of Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left">Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked &ldquo;[*]&rdquo; in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD STYLE="text-align: justify">Quality of Product</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1.</TD><TD STYLE="text-align: justify">SOL&Eacute;SENCE shall deliver to COLORESCIENCE the Bridge Solution and Exclusive Products in compliance
with the Product Specifications set forth in <B><U>Exhibit B</U></B> to this Agreement. <B><U>Exhibit B</U></B>, which is a part
hereof, may be modified from time to time upon the mutual written agreement of the Parties, including to incorporate the development
of new products, and shall be the final and exclusive description of the quality and all material properties of the Bridge Solution
and the Exclusive Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2.</TD><TD STYLE="text-align: justify">SOL&Eacute;SENCE, for itself and its Affiliates and suppliers, shall provide COLORESCIENCE with
full access to all data generated by SOL&Eacute;SENCE, its Affiliates and/or its suppliers on the Products which is necessary to
support COLORESCIENCE&rsquo;s regulatory filings or other governmental or regulatory approvals with respect to the Products or
which is necessary to respond to inquiries made by any governmental or regulatory authority with respect to the Products. In addition,
COLORESCIENCE, at its expense, shall have the right to conduct studies with the Products for regulatory and commercial purposes.
COLORESCIENCE will own all data and results from such studies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3.</TD><TD STYLE="text-align: justify">The Parties will each maintain traceability records necessary to permit a recall, field correction
or other notification to the field of any Product. Each Party will give telephonic notice (to be confirmed in writing) to the other
within twenty-four (24) hours of the receipt of any information which indicates a recall, field correction or other notification
to the field may be necessary. Except as otherwise required by applicable law, the decision to conduct and the right to control
a recall, field correction or any other notification to the field will be solely that of COLORESCIENCE. Each party will cooperate
fully with the other in connection with any such efforts. To the extent any recall, field correction or other notification to the
field is due to a breach by SOL&Eacute;SENCE of its obligations under this Agreement, or the negligence or willful misconduct of
SOL&Eacute;SENCE, SOL&Eacute;SENCE will replace the recalled or field corrected Products with conforming Products and will reimburse
COLORESCIENCE for all of COLORESCIENCE&rsquo;s reasonable and documented costs and expenses, both direct and indirect, actually
incurred by COLORESCIENCE in connection with the recall, field correction or other notification to the field, including, but not
limited to, the costs of retrieving any Product already delivered to customers and costs and expenses COLORESCIENCE is required
to pay for the replacement of the Product and the notification, shipping and handling charges. In all other cases, COLORESCIENCE
will reimburse SOL&Eacute;SENCE for all of SOL&Eacute;SENCE&rsquo;s reasonable and documented costs and expenses, both direct and
indirect, actually incurred by SOL&Eacute;SENCE in connection with the recall, field correction or other notification to the field
with respect to any Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD><TD STYLE="text-align: justify">Quantity of Product</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1.</TD><TD STYLE="text-align: justify">SOL&Eacute;SENCE shall deliver the quantity of each Product specified in each order by COLORESCIENCE
and COLORESCIENCE shall pay for such quantity of Product meeting the applicable Product Specifications and accepted by COLORESCIENCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>


<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         shall provide SOL&Eacute;SENCE with rolling forecasts of COLORESCIENCE&rsquo;s expected
                                         requirements for the Product (the &ldquo;<B><I>Forecasts</I></B>&rdquo;) as follows:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         Forecast shall provide an estimate of the quantity of each Product required during the
                                         next three (3) months.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         shall notify SOL&Eacute;SENCE of any changes to these Forecasts as soon as possible to
                                         allow SOL&Eacute;SENCE to make any necessary changes to production schedules. COLORESCIENCE
                                         shall not be responsible for paying for unneeded Products produced or ordered by SOL&Eacute;SENCE
                                         in accordance with any Forecast.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Order
                                         Processing and Deliveries</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         shall provide orders to SOL&Eacute;SENCE a minimum of 12 weeks in advance of the requested
                                         delivery date for Products and SOL&Eacute;SENCE shall accept each order placed by COLORESCIENCE
                                         within three (3) working days from receipt of such order. From time to time, SOL&Eacute;SENCE
                                         may notify COLORESCIENCE that due to scarcity of raw materials used to manufacture Products
                                         that the lead time for purchases has been extended. Notwithstanding anything in 8.1,
                                         SOL&Eacute;SENCE shall use every reasonable effort to meet COLORESCIENCE requested delivery
                                         dates that comply with the 12 week lead time. Acceptance of an order by SOL&Eacute;SENCE
                                         constitutes a complete and binding contract governed by the terms and conditions of this
                                         Agreement. Minimum quantities in regards to purchase orders placed by COLORESCIENCE with
                                         SOL&Eacute;SENCE for Finished Products A, B, and Next Gen Product(s) shall be for at
                                         least 15,000 units for the retail items or its equivalent in terms of total bulk quantities
                                         for orders placed that include samples or testers, unless otherwise agreed by the Parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         shall use best efforts to deliver the ordered Products to COLORESCIENCE at the location
                                         specified by COLORESCIENCE within 56 days of receipt of the applicable order, and in
                                         any event no later than 84 days of receipt of such order. The terms for delivery are
                                         Exworks SOL&Eacute;SENCE manufacturing location. All delivery conditions apply in accordance
                                         with the most recent Incoterms.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title
                                         to and risk of loss of Products covered by an accepted order shall transfer to COLORESCIENCE
                                         upon Delivery (see note above).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         may invoice COLORESCIENCE for each shipment of Products upon shipment. COLORESCIENCE
                                         shall pay each invoice for accepted Products within [*] days of receipt of such
                                         invoice. Solesence shall be due 0.5% interest per week for the first month and 1% thereafter
                                         on any outstanding, undisputed invoices after this [*] day period. Notwithstanding
                                         the foregoing, with respect to Invoice # [____________], COLORESCIENCE shall pay $[*]
                                         due pursuant to that invoice by <B>June</B> 15, 2018 and shall pay the remainder of that
                                         invoice within [*] days after April 15, 2018. SOLESENCE agrees to offer a [*]% discount
                                         and encourages COLORESCIENCE to attempt to pay invoices within [*] days.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product
                                         Returns and Non-Conforming Products</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         Product that does not meet the applicable Product Specifications, is delivered more than
                                         fifteen (15) days after the delivery date specified in an order placed and accepted in
                                         accordance with the requirements of this Article 8, or is otherwise not accepted by COLORESCIENCE
                                         (a &ldquo;<B><I>Non-conforming Product</I></B>&rdquo;) may be returned to SOL&Eacute;SENCE
                                         by COLORESCIENCE as set forth in this Article 9. An entire lot of Product may be returned
                                         to SOL&Eacute;SENCE by COLORESCIENCE as set forth in this Article 9 if a statistically
                                         significant sampling of that lot contains Non-conforming Product. Any acceptance of Non-conforming
                                         Product shall not be deemed a waiver of the requirement that SOL&Eacute;SENCE conform
                                         to the Product Specifications as to future Product.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         shall maintain a quality assurance program and adhere to the quality inspection and testing
                                         procedures described in <B><U>Exhibit D</U></B>. SOL&Eacute;SENCE shall subject all Product
                                         to such quality inspection testing procedures prior to delivery. SOL&Eacute;SENCE shall
                                         provide COLORESCIENCE with access to its quality inspection testing results upon request.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         Products shall be subject to inspection and acceptance by COLORESCIENCE at COLORESCIENCE&rsquo;s
                                         reasonable discretion. Payment shall not be deemed a waiver of COLORESCIENCE&rsquo;s
                                         right to inspection or acceptance. No inspection, acceptance or payment shall be binding
                                         on COLORESCIENCE as to latent defects. Without limiting any other rights or remedies
                                         it may have, COLORESCIENCE, at COLORESCIENCE&rsquo;s option, may (a) store, at SOL&Eacute;SENCE
                                         expense and subject to COLORESCIENCE&rsquo;s disposal, Non-conforming Products, (b) return
                                         Non-conforming Products to SOL&Eacute;SENCE, (c) require SOL&Eacute;SENCE to repair or
                                         replace any Non-conforming Products, (d) require SOL&Eacute;SENCE to issue a credit or
                                         refund to COLORESCIENCE of an amount equal to the amounts paid for any Non-conforming
                                         Products, and/or (e) require SOL&Eacute;SENCE to reimburse COLORESCIENCE for the costs
                                         incurred by COLORESCIENCE in procuring conforming goods from an alternate source to the
                                         extent that such costs exceed SOL&Eacute;SENCE&rsquo;s prices (even if not paid) for
                                         the Non-conforming Products. SOL&Eacute;SENCE acknowledges and agrees that the provisions
                                         of this Section shall not relieve SOL&Eacute;SENCE of any liability under the warranties
                                         set forth in this Agreement or which SOL&Eacute;SENCE would otherwise lawfully bear even
                                         after COLORESCIENCE&rsquo;s inspection and acceptance.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         Non-conforming Product returned to SOL&Eacute;SENCE, and all replacement Product shipped
                                         by SOL&Eacute;SENCE, will be at SOL&Eacute;SENCE&rsquo;s risk and expense. Risk of loss
                                         of Non-conforming Product returned to SOL&Eacute;SENCE will transfer to SOL&Eacute;SENCE
                                         upon delivery to SOL&Eacute;SENCE&rsquo;s designated carrier (Meaning: FOB shipping point,
                                         for COLORESCIENCE only).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Minimum Order Quantities per Exhibit A shall be reduced by an amount equal to the amount
                                         of Non-conforming Product returned to SOL&Eacute;SENCE multiplied by a factor of (two)
                                         2.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations
                                         and Warranties</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         Party represents and warrants to the other that it has taken all necessary actions on
                                         its part to authorize the execution, delivery and performance of its obligations undertaken
                                         in this Agreement and that this Agreement has been duly executed and delivered by and
                                         on its behalf and constitutes legal, valid and binding obligations enforceable against
                                         it in accordance with its terms.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         represents and warrants that:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.1.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">it
                                         has the full right, power and authority to grant all of the licenses and rights granted
                                         to COLORESCIENCE under this Agreement;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">there
                                         is no pending or, to the knowledge of SOL&Eacute;SENCE, threatened action, suit, proceeding
                                         or claim by any third party that any Solesence Technology infringes, misappropriates
                                         or violates any Intellectual Property Rights or other proprietary rights of any third
                                         party, and SOL&Eacute;SENCE has not received any written notice of such claim;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
                                         the knowledge of SOL&Eacute;SENCE, there is no infringement, misappropriation or violation
                                         by third parties of any Solesence Technology;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         owns all right, title and interest in and to the Patent Rights; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">none
                                         of the Patent Rights have been adjudged invalid or unenforceable, in whole or in part,
                                         and there is no pending or, to the knowledge of the Company, threatened action, suit,
                                         proceeding or claim by any third party challenging the validity or scope of any of the
                                         Patent Rights; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">each
                                         Product is and will</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">conform
                                         to the applicable Product Specifications; be produced in accordance with the quality
                                         inspection and testing program provided in Exhibit D; and be in compliance with all applicable
                                         laws and regulations;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                         new;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                         free from defects in design, material and workmanship;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                         conveyed with good and marketable title, free and clear of all liens or encumbrances;
                                         and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                         free from violation or infringement of any third party Intellectual Property Rights or
                                         other proprietary rights.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         warranties set forth in Sections 10.1, 10.2.1, 10.2.2, 10.2.3, 10.2.4, and 10.2.5 will
                                         survive any inspection, delivery, acceptance or payment by COLORESCIENCE. The warranties
                                         set forth in Sections 10.2.6(a) and 10.2.6(c) are made and effective at Delivery, are
                                         continuing and will remain in effect for the longer of Supplier&rsquo;s normal warranty
                                         period or for a period of 180 days following COLORESCIENCE&rsquo;s acceptance of the
                                         Product. The warranties set forth in Sections 10.2.6(b) and 10.2.6(d) are made and effective
                                         at Delivery. The warranty set forth in Section 10.2.6(e) is made and effective at Delivery,
                                         as is continuing and will remain in effect in perpetuity.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnification</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         shall defend, indemnify and hold harmless COLORESCIENCE and its Affiliates and their
                                         respective officers, directors, employees, subcontractors, customers, vendors and agents
                                         (the &ldquo;<B><I>COLORESCIENCE Indemnitees</I></B>&rdquo;) against and from all damages
                                         and claims for damages, suits, causes of action, proceedings, orders, injuries (including
                                         wrongful death) to persons and damages to property of COLORESCIENCE and others, liabilities,
                                         losses, fines, penalties, recoveries, judgments or executions, costs (including attorneys&rsquo;
                                         fees and costs, and environmental investigation, remediation, clean-up, response and/or
                                         settlement and other similar costs) brought by a third party (&ldquo;<B><I>Claims</I></B>&rdquo;)
                                         and which arise out of, are caused by, or are incident to: (a) any breach of this Agreement
                                         or any representation, warranty, or covenant contained herein; (b) any negligent or otherwise
                                         wrongful act, omission or conduct of any SOL&Eacute;SENCE Indemnitee (as defined below);
                                         (c) any failure of a Product to meet the applicable Product Specifications or be manufactured
                                         hereunder in accordance with applicable law; (d) any claim that the Solesence Technology
                                         and/or Solesence Trademarks or any manufacturing processes utilized by SOL&Eacute;SENCE
                                         infringes or misappropriates any Intellectual Property Rights or other proprietary rights
                                         of any third party; or (e) to the extent arising from, connected with or related to the
                                         Solesence Technology or any act, omission or conduct of any SOL&Eacute;SENCE Indemnitee:
                                         (i) the death or bodily injury of a person as a result of use of any Products manufactured
                                         by SOL&Eacute;SENCE; or (ii) any actual or alleged nonconformities, failures, malfunctions,
                                         defects or deficiencies (whether obvious or hidden and whether or not present in any
                                         Product or sample approved or accepted by COLORESCIENCE) in any Products, or in the design,
                                         construction, fabrication or manufacture of any Products (including the use and/or selection
                                         of materials and/or component parts thereof) or for the use thereof, or for any false
                                         advertising, fraud or misrepresentations or other claims related to the Products or related
                                         marketing or labeling materials; except to the extent caused by the gross negligence,
                                         willful misconduct or breach of this Agreement by any COLORESCIENCE Indemnitee.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 14; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         shall defend, indemnify and hold harmless SOL&Eacute;SENCE and its Affiliates and their
                                         respective officers, directors, employees, suppliers, subcontractors and agents (the
                                         &ldquo;<B><I>SOL&Eacute;SENCE Indemnitees</I></B>&rdquo;) harmless against and from all
                                         Claims which arise out of, are caused by, or are incident to any breach of this Agreement
                                         or any negligent or otherwise wrongful act, omission or conduct of any COLORESCIENCE
                                         Indemnitee, except to the extent caused by:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         failure of a Product to meet the Product Specifications;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         breach of any representation, warranty or covenant made by SOL&Eacute;SENCE under this
                                         Agreement; and/or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         gross negligence, willful misconduct or breach of this Agreement by any SOL&Eacute;SENCE
                                         Indemnitee.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnification
                                         Procedure. Promptly after receipt by a party seeking indemnification under this Article
                                         11 (an &ldquo;<B><I>Indemnitee</I></B>&rdquo;) of notice of any pending or threatened
                                         Claim against it, such Indemnitee shall give written notice to the Party from whom the
                                         Indemnitee is entitled to seek indemnification pursuant to this Article 11 (the &ldquo;<B><I>Indemnifying
                                         Party</I></B>&rdquo;) of the commencement thereof; provided that the failure so to notify
                                         the Indemnifying Party shall not relieve it of any liability that it may have to any
                                         Indemnitee hereunder, except to the extent the Indemnifying Party demonstrates that it
                                         is materially prejudiced thereby. The Indemnifying Party shall be entitled to participate
                                         in the defense of such Claim and, to the extent that it elects within ten (10) business
                                         days of its receipt of notice of the Claim from the Indemnitee, to assume control of
                                         the defense and settlement of such Claim (unless the Indemnifying Party is also a party
                                         to such proceeding and the Indemnifying Party has asserted a cross claim against the
                                         Indemnified Party or a court has otherwise determined that such joint representation
                                         would be inappropriate) with counsel reasonably satisfactory to the Indemnitee and, after
                                         notice from the Indemnifying Party to the Indemnitee of its election to assume the defense
                                         of such Claim, the Indemnifying Party shall not, as long as it diligently conducts such
                                         defense, be liable to the Indemnitee for any litigation costs subsequently incurred by
                                         the Indemnitee. No compromise or settlement of any Claim may be effected by the Indemnifying
                                         Party without the Indemnitee&rsquo;s written consent, which consent shall not be unreasonably
                                         withheld or delayed, provided no consent shall be required if: (a) there is no finding
                                         or admission of any violation of Applicable Laws or any violation of the rights of any
                                         person and no effect on any other claims that may be made against the Indemnitee; (b)
                                         the sole relief provided is monetary damages that are paid in full by the Indemnifying
                                         Party; and (c) the Indemnitee&rsquo;s rights under this Agreement are not restricted
                                         by such compromise or settlement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Limitation
                                         of Liability</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXCEPT
                                         IN THE EVENT OF A PARTY&rsquo;S (A) WILLFUL MISCONDUCT OR INTENTIONAL BREACH OR (B) GROSS
                                         NEGLIGENCE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
                                         PUNITIVE, OR INDIRECT DAMAGES (INCLUDING LOST PROFITS OR LOST REVENUES) ARISING FROM
                                         OR RELATING TO THIS AGREEMENT (INCLUDING BREACH OF THIS AGREEMENT) OR THE EXERCISE OF
                                         ITS RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING
                                         THE FOREGOING, NOTHING IN THIS ARTICLE 12 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (1)
                                         THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 11, OR (2) DAMAGES
                                         AVAILABLE FOR A PARTY&rsquo;S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE
                                         13.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 15; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidentiality</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the course of this Agreement the Parties have and will provide proprietary and confidential
                                         information to each other. The Parties are both &ldquo;<B><I>Disclosing Party</I></B>&rdquo;
                                         and &ldquo;<B><I>Receiving Party</I></B>&rdquo; as the case may be. The term &ldquo;<B><I>Confidential
                                         Information</I></B>&rdquo; as used herein shall mean proprietary information including
                                         but not limited to any information, know-how, data, technology, analytical data, mixtures,
                                         recipes, formulas, specifications, manufacturing procedures, customer information, strategies
                                         and business plans as well as product samples that are disclosed or provided to the Receiving
                                         Party or obtained by their evaluation (whether tangible or in electronic form). All Confidential
                                         Information need not be marked as &ldquo;Confidential&rdquo; or &ldquo;Proprietary&rdquo;
                                         provided that the circumstances of disclosure would lead a reasonable person in the relevant
                                         field to understand that such information was confidential or proprietary.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Receiving Party shall: (i) hold in strict confidence all Confidential Information disclosed
                                         by the Disclosing Party and protect such Confidential Information with the same standard
                                         of care the Receiving Party affords its own Confidential Information, but no less than
                                         reasonable care; and (ii) not disclose the Confidential Information to any third party
                                         except for its employees, employees of its Affiliates, or its attorneys, accountants,
                                         consultants, agents representatives, contractors, suppliers, potential investors, lenders
                                         or acquirers whose duties justify the need to know such Confidential Information and
                                         who are bound by confidentiality obligations at least as restrictive as those set forth
                                         in this Article 13.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Receiving Party shall not use the Confidential Information for any purpose other than
                                         the execution of this Agreement, not file for any patent or other intellectual property
                                         registration claiming, disclosing, or referencing such Confidential Information and not
                                         commercially exploit such Confidential Information without the written consent of the
                                         Disclosing Party.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         foregoing restrictions on disclosure and use shall not be applicable to any Confidential
                                         Information which the Receiving Party can prove through tangible evidence that</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">are
                                         in the public domain at the time of disclosure;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">are
                                         published or otherwise become part of the public domain through no fault of the Receiving
                                         Party;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">were
                                         in the possession of the Receiving Party at the time of disclosure by the Disclosing
                                         Party as shown by prior written records or became available from a third party who has
                                         the right to legally disclose it and who is not subject to a duty of confidentiality
                                         to the Disclosing Party or any other party;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">were
                                         independently developed by the Receiving Party without using or making any reference
                                         to the Confidential Information;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">are
                                         required to be disclosed pursuant to a law, regulation, rule or ordinance of any governmental
                                         body or court having jurisdiction over either Party provided that the Receiving Party
                                         has given prompt written notice to the Disclosing Party of any such requirement prior
                                         to any disclosure, and provides the Disclosing Party with the opportunity to prevent
                                         or limit such disclosure.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidential
                                         Information shall not be considered within the above exceptions merely because the Confidential
                                         Information is embraced by more general information within the exceptions. Any combination
                                         of features of Confidential Information shall not be considered within the above exceptions
                                         unless the combination itself and its principles of operation are within the exceptions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 16; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Receiving Party shall, upon termination of this Agreement or earlier written request
                                         of the Disclosing Party, promptly return all Confidential Information received from the
                                         Disclosing Party and destroy and delete (and confirm such destruction and deletion in
                                         writing) all copies thereof (whether tangible or in electronic form) containing Confidential
                                         Information.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         as expressly provided herein, neither this Agreement nor the disclosure of Confidential
                                         Information shall be deemed to constitute the grant of any right or license under any
                                         Confidential Information. Confidential Information shall remain the exclusive property
                                         of the Disclosing Party.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         obligations of confidentiality and nonuse set forth in this Article 13 shall survive
                                         for a period of seven (7) years beyond the termination or expiration of this Agreement;
                                         provided, however, that in the case of Confidential Information comprising a trade secret
                                         of the Disclosing Party, such obligations shall continue for as long as such Confidential
                                         Information qualifies as a trade secret under applicable law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intellectual
                                         Property</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ownership.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Background
                                         IP. All Intellectual Property Rights owned or controlled by each Party prior to the Effective
                                         Date or developed independently of the activities performed under or contemplated by
                                         this Agreement and without access or reference to the other Party&rsquo;s intellectual
                                         property or Confidential Information (&ldquo;<B><I>Background IP</I></B>&rdquo;), shall
                                         remain the sole property of the Party. No right or license is granted in either Party&rsquo;s
                                         Background IP except as expressly state herein.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         Technology. All COLORESCIENCE Technology and all Improvements made by or on behalf of
                                         either Party to the COLORESCIENCE Technology shall be owned exclusively by COLORESCIENCE.
                                         To the extent that SOL&Eacute;SENCE acquires any interest in any Improvements to the
                                         COLORESCIENCE Technology, SOL&Eacute;SENCE agrees to assign and hereby assigns such interest
                                         to COLORESCIENCE. Any trademarks or copyrights filed by COLORESCIENCE on products related
                                         to independently created or Joint Intellectual Property shall be solely owned by COLORESCIENCE.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
                                         Technology. All SOL&Eacute;SENCE Technology and all Improvements made by or on behalf
                                         of either Party to the SOL&Eacute;SENCE Technology shall be owned exclusively by SOL&Eacute;SENCE.
                                         To the extent that COLORESCIENCE acquires any interest in any Improvements to the SOL&Eacute;SENCE
                                         Technology, including, without limitation, the Bridge Solution and the Innovation Solution
                                         Actives, COLORESCIENCE agrees to assign and hereby assigns such interest to SOL&Eacute;SENCE.
                                         Notwithstanding the foregoing, any Improvements made by or on behalf of COLORESCIENCE
                                         to SOL&Eacute;SENCE Technology shall not be used or disclosed by SOL&Eacute;SENCE for
                                         the benefit of any third party without COLORESCIENCE&rsquo;s prior written consent. Intellectual
                                         Property Rights associated with manufacturing processes that are generally applicable
                                         to SOL&Eacute;SENCE&rsquo;s industry and do not contain or reference COLORESCIENCE Technology
                                         shall be the exclusive property of SOL&Eacute;SENCE, subject to Section 14.1.4 below.
                                         For the avoidance of doubt, SOL&Eacute;SENCE shall be free to use, license, and/or sell
                                         such manufacturing processes for any application outside of the Exclusive Application
                                         at SOL&Eacute;SENCE&rsquo;s sole discretion, provided that COLORESCIENCE&rsquo;s rights
                                         under this Agreement are not impaired by such use, license, or sale.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Joint
                                         IP. Inventorship of inventions conceived or reduced to practice in connection with the
                                         activities performed under or contemplated by this Agreement shall be determined by application
                                         of U.S. patent laws pertaining to inventorship. All Intellectual Property Rights developed,
                                         created, generated, conceived, authored or reduced to practice jointly by employees or
                                         contractors of COLORESCIENCE or its Affiliates on one hand, and employees or contractors
                                         of SOL&Eacute;SENCE or its Affiliates on the other hand (&ldquo;<B><I>Joint IP</I></B>&rdquo;),
                                         shall be jointly owned by COLORESCIENCE and SOL&Eacute;SENCE. COLORESCIENCE shall have
                                         the exclusive right to market, distribute and sell products covered under Joint IP (&ldquo;<B><I>Joint
                                         Products</I></B>&rdquo;) and such Joint Products developed will be added to <B><U>Exhibit
                                         B</U></B>. Notwithstanding anything to the contrary herein, Finished Product A and Finished
                                         Product B shall be deemed to be Joint Products excluding the Innovation Solution Active(s)
                                         incorporated therein. During the Term, SOL&Eacute;SENCE shall have the exclusive right
                                         to manufacture (subject to the provisions of Article 5) Joint Products for all applications,
                                         including for COLORESCIENCE for use within the Exclusive Field, as well as the exclusive,
                                         royalty free right to sell products using the Joint IP for any application outside of
                                         the Exclusive Field (but subject to the limitations of Article 3, including the negative
                                         covenants set forth in Section 3.4).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         the foregoing, should COLORESCIENCE&rsquo;s cumulative purchases of Finished Product
                                         exceed 300,000 units, COLORESCIENCE shall become the sole owner of all Joint IP and all
                                         Intellectual Property Rights and SOL&Eacute;SENCE&rsquo;s interest therein, including
                                         to the formula, related to that Finished Product, and SOL&Eacute;SENCE agrees to assign
                                         and upon such occurrence hereby does assign its entire right, title, and interest therein
                                         to COLORESCIENCE.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         Party shall enter into binding agreements obligating all employees, consultants and contractors
                                         performing activities under or contemplated by this Agreement, to assign to such Party
                                         his or her interest in any Intellectual Property Rights conceived, authored or reduced
                                         to practice in the course of such activities.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Enforcement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notification
                                         of Infringement. Each Party shall promptly notify the other of any material infringement
                                         or misappropriation of, or proceeding or claim involving, any COLORESCIENCE Technology,
                                         SOL&Eacute;SENCE Technology, or Joint IP by a third party or parties, as soon as the
                                         notifying Party learns of such infringement, misappropriation, proceeding, or claim,
                                         and shall provide the other Party with any available evidence of such infringement, misappropriation,
                                         proceeding, or claim.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COLORESCIENCE
                                         or any of its Affiliates or sublicensees shall have the first right, but not the obligation,
                                         using counsel of its choice, to enforce the Patent Rights against any actual or suspected
                                         infringement of the Patent Rights with respect to the development or commercialization
                                         of a Competing Product in the Field and Territory by a third party or defend any declaratory
                                         action with respect thereto brought by such third party (a &ldquo;<B><I>Patent Action</I></B>&rdquo;),
                                         at its expense, and SOL&Eacute;SENCE shall provide all reasonable assistance to COLORESCIENCE
                                         in such Patent Action, including joining, at COLORESCIENCE&rsquo;s reasonable expense,
                                         such Patent Action if necessary to maintain the Patent Action, or to seek additional
                                         or alternative damages or injunctive relief under such Patent Action.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                         (i) COLORESCIENCE elects in writing not to bring or defend a Patent Action or (ii) within
                                         sixty (60) days following a written request by SOL&Eacute;SENCE to bring or defend a
                                         Patent Action and confirmation of facts reasonably supporting existence of such actual
                                         or suspected infringement with respect to the Patent Rights, COLORESCIENCE and its Affiliates
                                         and sublicensees fail to bring or defend a Patent Action or take other commercially reasonable
                                         action to protect the Patent Rights from such infringement, or to abate such infringement
                                         (which may in the discretion of COLORESCIENCE include, without limitation, negotiations
                                         for a settlement), then SOL&Eacute;SENCE or its Affiliates or other licensees shall have
                                         the right, but not the obligation, at its sole discretion, to institute a Patent Action
                                         in its own name using counsel of its choice, at its own expense, and COLORESCIENCE shall
                                         provide all reasonable assistance to SOL&Eacute;SENCE in such Patent Action, including
                                         joining, at SOL&Eacute;SENCE&rsquo;s reasonable expense, such Patent Action if necessary
                                         to maintain the Patent Action, or to seek additional or alternative damages or injunctive
                                         relief under such Patent Action.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 18; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         recovery received as a result of any Patent Action shall be used first to reimburse the
                                         Parties for their costs and expenses (including attorneys&rsquo; and professional fees)
                                         incurred in connection with such Patent Action (and not previously reimbursed), and any
                                         remaining amount of such recovery shall be awarded to the Party that brought or defended
                                         the suit; provided that if both Parties jointly bring or defend a Patent Action any amount
                                         recovered will be applied pro-rata (based on the agreed allocation of costs and expenses
                                         to be borne by each Party in such action or suit) for the costs and expenses with respect
                                         to such action or suit (including reasonable attorneys&rsquo; fees and costs) and the
                                         remaining amounts shall be similarly divided on a pro-rata basis unless otherwise agreed
                                         by the Parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Maintenance.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Maintenance
                                         of Existing Intellectual Property Registrations. SOL&Eacute;SENCE shall prosecute and
                                         maintain the Patent Rights and any trademark or copyright registrations related to any
                                         SOL&Eacute;SENCE Technology and any Products in each country in the Territory in which
                                         any such Patent Rights and any trademark or copyright registrations exist. In the event
                                         that SOL&Eacute;SENCE fails after reasonable written notice by COLORESCIENCE to prosecute
                                         or maintain any such Patent Rights and any trademark or copyright registrations, COLORESCIENCE
                                         shall have the right but not the obligation to do so in such instance, either in its
                                         own name or in the name of SOL&Eacute;SENCE.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prosecution
                                         and Maintenance of Patent Applications for Improvements to SOL&Eacute;SENCE Technology.
                                         In the event that any Improvements to SOL&Eacute;SENCE Technology conceived or reduced
                                         to practice in the performance of this Agreement, the Parties shall consult each other
                                         in making a determination of whether to file one or more applications to obtain patents
                                         claiming such Improvement. SOL&Eacute;SENCE shall have the first right to file and prosecute
                                         patent applications claiming such Improvement. In the event that SOL&Eacute;SENCE elects
                                         not to file any patent applications for any such Improvement, COLORESCIENCE shall have
                                         the right, but not the obligation, to file and prosecute such patent application(s) in
                                         the name of SOL&Eacute;SENCE (or an Affiliates designated by SOL&Eacute;SENCE) and SOL&Eacute;SENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by COLORESCIENCE. In
                                         the event that SOL&Eacute;SENCE files but subsequently elects to abandon any patent application
                                         with respect to any such Improvement, COLORESCIENCE shall have the right, but not the
                                         obligation, to prosecute such patent application(s) in the name of SOL&Eacute;SENCE (or
                                         the SOL&Eacute;SENCE Affiliate named as the owner of record). In each such case, COLORESCIENCE
                                         shall provide SOL&Eacute;SENCE with written notice of its exercise of such right and
                                         SOL&Eacute;SENCE and its Affiliates shall reasonably cooperate in any such efforts by
                                         COLORESCIENCE. To the extent that any patent application covering any Improvement filed
                                         pursuant to this Section 14.3.2 matures into an issued patent, such patent shall be included
                                         in the Patent Rights and thereafter subject to Section 14.3.1.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prosecution
                                         and Maintenance of Patent Applications for Joint IP. In the event that any Joint IP is
                                         conceived or reduced to practice in the performance of this Agreement, the Parties shall
                                         consult each other in making a determination of whether to file one or more applications
                                         to obtain patents claiming such Improvement. COLORESCIENCE shall have the first right
                                         to file and prosecute patent applications claiming such Joint IP, and SOL&Eacute;SENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by COLORESCIENCE. In
                                         the event that COLORESCIENCE elects not to file any patent applications for any such
                                         Joint IP, SOL&Eacute;SENCE shall have the right, but not the obligation, to file and
                                         prosecute such patent application(s) in the name of SOL&Eacute;SENCE and COLORESCIENCE
                                         (or an Affiliates designated by SOL&Eacute;SENCE or COLORESCIENCE) and COLORESCIENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by SOL&Eacute;SENCE.
                                         In the event that COLORESCIENCE files but subsequently elects to abandon any patent application
                                         with respect to any such Improvement, SOL&Eacute;SENCE shall have the right, but not
                                         the obligation, to prosecute such patent application(s) in the name of SOL&Eacute;SENCE
                                         and COLORESCIENCE (or the SOL&Eacute;SENCE or COLORESCIENCE Affiliate named as the owners
                                         of record). In each such case, SOL&Eacute;SENCE shall provide COLORESCIENCE with written
                                         notice of its exercise of such right and COLORESCIENCE and its Affiliates shall reasonably
                                         cooperate in any such efforts by SOL&Eacute;SENCE.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notices</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         notices in relation to a breach of this agreement or any demand notes to the other Party
                                         shall be in writing and shall be send to the following contact persons:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
COLORESCIENCE:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted Ebel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Function:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Business Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2141 Palomar Airport Drive</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlsbad, CA 92011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">760-565-5736</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
SOL&Eacute;SENCE:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Cureton</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Function:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Commercial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1319 Marquette Drive</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Romeoville, Illinois 60446</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">630-771-6733</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Force
                                         Majeure</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deliveries
                                         or acceptance of the Product may be delayed or suspended by either of the Parties in
                                         the event of Act of God, war, riot, fire, explosion, accident, flood, sabotage, governmental
                                         laws, regulations, order or action, national defense requirements or any other event
                                         beyond the reasonable control of such Party (such event, a &ldquo;Force Majeure Event&rdquo;),
                                         any of which events prevent the manufacture, shipment, or acceptance or a shipment of
                                         the Product if, because of such event, SOL&Eacute;SENCE is unable to supply part or total
                                         demand for the Product, including due to scarcity of raw materials or if COLORESCIENCE,
                                         because of any such extent, is unable to accept part or total of quantity contracted
                                         for the affected Party shall be exempted to such extent from its obligations hereunder
                                         with respect to the particular delivery involved upon giving prompt notice of such event
                                         to the other Party. The other Party shall be likewise exempted from its corresponding
                                         obligations, but this Agreement shall otherwise remain unaffected.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 20; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSIGNMENT.
                                         This Agreement shall be binding upon and inure to the benefit of, the successors and
                                         permitted assigns of the parties. COLORESCIENCE shall have the right to assign this Agreement
                                         upon written notice to SOL&Eacute;SENCE. SOL&Eacute;SENCE shall have the right to assign
                                         this Agreement only to the acquirer of all or substantially all of its business to which
                                         this Agreement pertains, including all Intellectual Property Rights licensed hereunder.
                                         SOL&Eacute;SENCE shall not assign any Intellectual Property Rights hereunder except to
                                         an assignee who has assumed all of the rights and obligations under this Agreement. An
                                         assigning party shall give prompt notice of assignment to the other party. Any assignment
                                         not in compliance with this Section shall be null and void.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NO
                                         THIRD PARTY BENEFICIARIES. Nothing in this Agreement will confer any benefit or right
                                         upon any third party except for the Parties&rsquo; successors or permitted assignees.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">RELATIONSHIP
                                         OF THE PARTIES. Nothing in this Agreement and no action taken by the Parties under this
                                         Agreement will constitute a partnership, joint venture or agency relationship between
                                         the Parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COUNTERPARTS.
                                         This Agreement may be executed in any number of counterparts, and by the Parties on separate
                                         counterparts, but will not be effective until each Party has executed at least one counterpart.
                                         Each counterpart will constitute an original of this Agreement, but all the counterparts
                                         together will constitute but one and the same agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COSTS
                                         AND EXPENSES. Each Party will pay its own costs relating to the negotiation, preparation,
                                         execution and performance of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENTIRE
                                         AGREEMENT. This Agreement, together with all Attachments and any other documents incorporated
                                         herein constitute the entire agreement of the Parties with respect to the subject matter
                                         in this Agreement, and supersede all prior and contemporaneous understandings, agreements,
                                         representations and warranties, both written and oral, with respect to the subject matter.
                                         Each Party acknowledges that, in entering into this Agreement, it has not relied on any
                                         statement, representation, warranty or agreement of the other Party other than as expressly
                                         contained in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMENDMENTS.
                                         Any amendment of or variation to this Agreement must be in writing and signed by authorized
                                         representative(s) of both Parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">WAIVER.
                                         No failure or delay by either Party in exercising any right or remedy provided under
                                         this Agreement or by law will constitute a waiver of that or any other right or remedy,
                                         nor will any single or partial exercise of any right or remedy preclude any other or
                                         further exercise of it or the exercise of any other right or remedy. No waiver under
                                         this Agreement is effective unless it is in writing and signed by authorized representative(s)
                                         of both Parties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SEVERABILITY.
                                         If any provision in this Agreement, for any reason, is invalid, illegal or unenforceable,
                                         in whole or in part, in any jurisdiction, such invalidity, illegality or unenforceability
                                         will not affect any other provision of this Agreement or invalidate or render unenforceable
                                         such provision in any other jurisdiction. Upon a determination that any provision is
                                         invalid, illegal or unenforceable, the Parties will negotiate in good faith to modify
                                         this Agreement to effect the original intent of the Parties as closely as possible in
                                         a mutually acceptable manner in order that the transactions contemplated herein are consummated
                                         as originally contemplated to the greatest extent possible.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 21; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NOTICES.
                                         All notices provided in connection with this Agreement must be in writing and will be
                                         deemed to have been given (a) when delivered by hand; (b) when delivered if sent by an
                                         internationally recognized commercial courier; (c) on the third (3<SUP>rd</SUP>) day
                                         after the first post-mark of the sender&rsquo;s postal service if sent by first class
                                         mail, postage prepaid (return receipt requested, if available). The notices must be sent
                                         to the respective Parties at the address of the contact person set forth in the &ldquo;Description
                                         of the Parties&rdquo; (or at such other address for a Party as may be specified in a
                                         notice given in accordance with this Section).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICABILITY
                                         OF SECTION 365(N) OF THE BANKRUPTCY CODE. In the event SOL&Eacute;SENCE becomes a debtor
                                         under Title 11 of the U.S. Code (the <B>&ldquo;<I>Bankruptcy Code</I>&rdquo;</B>), this
                                         Agreement shall be deemed to be, for purposes of Section 365(n) of Title 11, a license
                                         to &ldquo;Intellectual Property&rdquo; as defined therein and COLORESCIENCE and its Affiliates,
                                         and each of their successors and assigns as licensees shall have the rights and elections
                                         as specified in the Bankruptcy Code. Specifically, if SOL&Eacute;SENCE, as a debtor-in-possession
                                         or a trustee-in-bankruptcy in a case under the Bankruptcy Code, rejects this Agreement,
                                         COLORESCIENCE and its Affiliates, successors and assigns may elect to retain their rights
                                         under this Agreement as provided in Section 365(n).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">RESPONSIBILITY
                                         FOR SUPPLIER. SOL&Eacute;SENCE shall be responsible for any and all acts or omissions
                                         of its suppliers, manufacturers, contractors, agents, and Affiliates in each case where
                                         any action, or the corresponding responsibility, is required or permitted to be performed
                                         by either SOL&Eacute;SENCE or its suppliers, manufacturers, contractors, agents, and
                                         Affiliates and all such acts or omissions in such circumstances shall be deemed acts
                                         or omissions of SOL&Eacute;SENCE hereunder.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">GOVERNING
                                         LAW. This Agreement shall be governed by and construed in accordance with the Laws of
                                         the United States and the State of Illinois, as applied to agreements entered into and
                                         to be performed entirely within Illinois between Illinois residents, without giving effect
                                         to the principles thereof relating to the conflicts of Laws. The Parties consent to the
                                         exclusive jurisdiction and venue of the State and Federal courts having within their
                                         jurisdiction Chicago, Illinois, and hereby agree to irrevocably waive all objections
                                         to personal jurisdiction, venue and <I>forum non conveniens.</I> The Parties exclude
                                         application of the United Nations Convention on Contracts for the International Sale
                                         of Goods. COLORESCIENCE AND SOL&Eacute;SENCE HEREBY IRREVOCABLY WAIVE THEIR RESPECTIVE
                                         RIGHTS TO TRIAL BY JURY IN RESPECT OF ANY DISPUTES ARISING UNDER OR RELATED TO THIS AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature
page follows.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 22; Value: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center; text-indent: -35.45pt"></P>


<P STYLE="margin: 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF, this Amended and Restated Joint Development &amp; Supply Agreement has been duly executed on behalf of the parties
as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 94%; margin-left: 0.5in">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%"><B>COLORESCIENCE, Inc. </B></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 40%"><B>SOL&Eacute;SENCE, LLC</B></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">/s/
Ted Ebel </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/
Kevin Cureton </TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name:
Ted Ebel</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Kevin Cureton</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Title:
Chief Business Officer</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"> Title: Chief Commercial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual Minimum Order Quantities</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border: Black 1pt solid; text-align: center; font-weight: bold; padding-left: 5.4pt; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Solution &ndash; TiO2</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation
    Active Solution &ndash; TiO2</FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold; padding-bottom: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation Active Solution &ndash; ZnO</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt; padding-bottom: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price per kg</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">$[*]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">$[*]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">$[*]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017 Minimum Annual Purchases (kg)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    Obligations Fulfilled</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018 Minimum Annual Purchases (kg)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
    &ndash; combined</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019 Minimum Annual Purchases (kg)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
    &ndash; combined</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
    &amp; beyond Minimum Annual Purchases (kg)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*]%
    growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth is sufficient</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">[*]%
    growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth
    is sufficient</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finished
    Products</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finished
    Products A &amp; B</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price
    per Ounce</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finished
Product A: $[*] plus carton, insert, and packaging components, to increase by not more than [*]% per year&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finished
        Product B: $[*] plus carton, insert, and packaging components, to increase by not more than [*]% per year</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018
    Minimum Order Quantity (units)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*],
    if Solesence has filed and received approval by the Australian TGA to sell both Finished Product A and Finished Product B
    as registered sunscreens.&nbsp;&nbsp;If not, the MOQ will be [*].&nbsp;&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019
    Minimum Order Quantity (units)</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
    Minimum Order Quantity (units)</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021
    Minimum Order Quantity (units)</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022
    and beyond Minimum Order Quantity (units)</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]%
    annual increase from previous year for the duration of the Agreement</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price
                                         per ounce for the Finished Products is the anticipated price per ounce for a &ldquo;Full
                                         Face Product&rdquo; anticipated to be developed by SOL&Eacute;SENCE assuming a per ounce
                                         size of [*] to [*] ounces. In the event that SOL&Eacute;SENCE develops a &ldquo;Body
                                         Product&rdquo;, such price per ounce will be lower. Both parties will work to identify
                                         the appropriate unit price regardless of format to enable Client to support a gross margin
                                         on such product of [*]% to [*]%, not including packaging cost.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
B</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product
Specifications</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 33%; border: Black 1pt solid; text-align: center; padding-bottom: 3pt; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TEST</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 3pt; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRODUCT</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 3pt; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SPECIFICATION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actives
    Level (%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation Active &ndash; [*],</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
    &ndash; [*] %</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation Active &ndash; [*]</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
    &ndash; [*] %</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product A</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
    &ndash; [*]%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hydrophobicity</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation Actives</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">PASS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Photostability</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation Actives</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">PASS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">USP
    monograph</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Innovation Actives</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">PASS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Microbial
    Limits</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Product A, Product B</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    than [*]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
C</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
Rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border: Black 1pt solid; text-align: center; text-transform: uppercase; font-weight: bold; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">serial
    number</FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; text-align: center; text-transform: uppercase; font-weight: bold; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">jurisdiction</FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; text-align: center; text-transform: uppercase; font-weight: bold; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">filing
    date</FONT></TD>
    <TD STYLE="width: 52%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: center; text-transform: uppercase; font-weight: bold; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-transform: uppercase; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">9,139,737</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; text-align: center; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">United
    states</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; text-align: center; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">11/21/2011</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MULTIFUNCTIONAL
    COATED POWDERS AND HIGH SOLIDS DISPERSIONS</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
D</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quality
Assurance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: Black 1pt solid; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TEST DESCRIPTION</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>METHOD</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>APPLICABLE
    PRODUCT</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actives Level (%)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">X-ray
    Fluorescence,</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Actives, Innovation Active - [*], Product B</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actives Level (%)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">QA-01-625</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product
    A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hydrophobicity</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">QA-01-800</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Actives, Innovation Actives</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Photostability</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">QA-01-1882</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Active, Innovation Active [*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Photostability</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">QA-01-1883</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovation
    Active [*]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">USP monograph</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    USP monograph</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Active, Innovation Actives</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Microbial
    Limits</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">USP</FONT>&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bridge
    Active, Innovation Active, Product A, Product B</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
E</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL&Eacute;SENCE
Trademarks</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sol&eacute;sence<SUP>&reg;</SUP></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="nanx8k052418001.jpg" ALT="(SOLESENCE LOGO)"><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked &ldquo;[*]&rdquo; in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>EXHIBIT
F</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Reserved Rights</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Any
                                         Environmental Protection Product containing (i) a prescription (as defined by the U.S.
                                         FDA) active ingredient and (ii) the Sol&eacute;sence Technology. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Any
                                         Environmental Protection Product comprising an over-the-counter (as defined by the U.S.
                                         FDA) active ingredient and the Sol&eacute;sence Technology, wherein such over-the-counter
                                         active ingredient is not permitted under the U.S. FDA sunscreen monograph (Sunscreen
                                         Drug Products for Over-the-Counter Human Use) to be used in combination with sunscreen
                                         active ingredients within the United States.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Any
                                         Environmental Protection Product wherein the primary active ingredient is a therapeutic
                                         active ingredient that is enhanced when used in combination with the Sol&eacute;sence
                                         Technology.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Any
                                         product supplied to </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">[*]
                                         <FONT STYLE="text-transform: none">or </FONT>[*]<FONT STYLE="text-transform: none">,
                                         except for products that utilize the Exclusive Application or use or contain </FONT>[*]
                                         <FONT STYLE="text-transform: none">or </FONT>[*]<FONT STYLE="text-transform: none">.
                                         </FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Any
                                         product intended for spray application to human skin.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nanx8k052418001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nanx8k052418001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ /0#Z P$1  (1 0,1 ?_$ *P   (# 0$! 0
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MJ2S3-?/R=M7Z%H+>$QVP:SS<?B4R6^J&RVFTMM/.(;0 E"$LJ  '( 4[&3@
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MSTWXD^-,+/'B'Q'5R5Y#*NG'%HXL^E5>_.G^;SV;^>A+92R64MV<40JZ;WY
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5X>#RJK<<^9]3S*PX6KNN*.%"A?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
